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A CLINICALLY RELEVANT MOUSE MODEL OF CISPLATIN-INDUCED KIDNEY 
INJURY 
Cierra Nichole Sharp 
May 17, 2018 
     Cisplatin is a potent chemotherapeutic used for the treatment of many solid cancers, 
including testicular, ovarian, and lung cancer.  Cisplatin causes many adverse side 
effects, of which nephrotoxicity leading to acute kidney injury is dose-limiting.  
Approximately 30% of patients will develop nephrotoxicity with cisplatin, and will either 
have their next dose of cisplatin lowered, skipped, or be switched to a less nephrotoxic 
chemotherapeutic altogether.  These outcomes are not ideal when trying to treat cancer.       
     Previously, it was believed that patients could recover from cisplatin-induced acute 
kidney injury with little to no lasting effects, but recent longitudinal studies have shown 
this is not the case.  Patients who develop acute kidney injury are ten times more likely to 
develop chronic kidney disease, which often requires dialysis and has an increased 
mortality rate.  Unfortunately, there are no treatment options available for either acute 
kidney injury or chronic kidney disease.  This may be due to the fact that the mouse 
model used to study cisplatin-induced kidney injury is not physiologically relevant to 
patients.  The work featured in this dissertation aims to develop a clinically relevant 
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mouse model of cisplatin-induced kidney injury by developing a cisplatin dosing regimen 
that recapitulates the type of dosing regimen patients receive.  In order to further improve 
clinical relevancy, the effects of aging and cancer are also explored with this mouse 
model.  The ultimate goal of this work is to use this model to identify a novel target and 
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BACKGROUND AND INTRODUCTION 
 
1.1 Cisplatin 
Cisplatin (cis-diamminedichloridoplatinum [II]) is one of the few platinum-based 
chemotherapeutics used clinically, and arguably one of the most successful 
chemotherapeutics to be used (2, 3).  Its potential use in cancer treatment began in the 
1960s when Barret Rosenberg was studying E.Coli cellular division and the role 
electrical currents played in proper cell division (2, 4).  In his studies, inert platinum 
electrodes immersed in ammonium chloride buffer inhibited cell division, and this 
inhibition led to the hypothesis that the platinum salt produced by hydrolysis of the 
platinum electrode may have potential as a cancer therapeutic (5).  Initial studies in Swiss 
white mice with Sarcoma confirmed that cisplatin could cure cancer (2).  
Since its FDA approval in the early 1970s, cisplatin has been used in the treatment of 
many solid tumor cancers (2, 6).  Cisplatin is efficacious for the treatment of ovarian 
cancer, head and neck cancer, bladder cancer, cervical cancer, melanoma, certain 
lymphomas, and non-small cell lung cancer (NSCLC) (2, 6).  The therapeutic dosing 
regimen for treatment of these cancers with cisplatin varies greatly.  For example, 
patients with ovarian cancer receive one, high dose (90-270 mg/m2) of cisplatin 
intravenously (2, 7).  However, for head and neck cancers, cisplatin is often used as a 
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chemosensitization step prior to treatment with radiation.  Furthermore, patients with 
NSCLC often receive 60-100 mg/m2 cisplatin in combination with other antineoplastic 
agents once every 21 days for multiple cycles (2)   
Cisplatin’s antitumor efficacy is based on its ability to induce apoptosis in cancer 
cells (2, 6, 8).  Once in the bloodstream, cisplatin can enter into cells by simple diffusion, 
or by uptake via copper transport proteins.  Inside the cell, cisplatin encounters a low 
chloride concentration, and therefore one of its chloro-ligands is rapidly replaced with 
water.  This replacement gives cisplatin a positive charge, and this intermediate species 
can readily bind to guanine bases of DNA to form adducts (8).  The formation of these 
DNA adducts initiates apoptotic signaling pathways, resulting in cell death. 
A general downside to use of chemotherapeutics (including cisplatin) is that the 
mechanism of action for killing rapidly dividing cancer cells also kills normal, rapidly 
dividing cells in the body, including cells lining the gastrointestinal tract (2).  Due to this 
chemotherapeutics, like cisplatin, cause nausea and hair loss.  However, cisplatin has 
several other severe toxicities.  Of note, cisplatin has a high rate of ototoxicity, and older 
patients run a risk of hematological toxicity with cisplatin (9).  However, the dose-
limiting side effect of cisplatin is nephrotoxicity.   
1.2 Cisplatin-Induced Nephrotoxicity 
The mechanisms involved in cisplatin nephrotoxicity are complex.  A large portion of 
cisplatin binds to albumin in the blood, and bound cisplatin is freely filtered through 
glomeruli in the kidney (2, 9, 10).  Filtered cisplatin is taken up by organic cation 
transporter 2 (OCT2) and copper transporter 1 (Ctr1) in proximal tubule epithelial cells, 
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leading to a five time higher concentration of cisplatin in these cells compared to the 
serum (11-13).  Once inside tubular cells, cisplatin has a direct toxic effect via DNA 
alkylation and subsequent activation of apoptotic signaling pathways (9, 10, 14, 15).  In 
addition, cisplatin can be converted to highly reactive, thiol conjugate intermediates.  
These intermediates readily bind to DNA, RNA, and proteins leading to enhanced renal 
tubular cell death (9, 10, 14, 15).  Whereas cell death is therapeutic in the context of 
cancer, the high level of tubular cell death causes severe nephrotoxicity. 
1.3 Pathophysiology of Cisplatin-Induced Nephrotoxicity  
The two main forms of cell death involved in cisplatin nephrotoxicity are apoptosis 
and necrosis (9, 10, 14, 15).  Specifically, cisplatin activates the intrinsic apoptotic 
signaling pathway (9).  Injury to tubular cells from cisplatin leads to an accumulation of 
Bax, a BCL2 pro-apoptotic protein, in the mitochondria (16).  This accumulation of Bax 
causes the release of cytochrome c, and downstream activation of initiator and effector 
caspases, particularly the cleavage and activation of Caspase-3 (9).     
Necrosis caused by cisplatin is largely mediated by inflammation, a major contributor 
to the pathophysiology of cisplatin-induced nephrotoxicity (9, 10, 14, 15).  TNFα is 
produced by resident kidney cells, and levels increase in the kidney, blood, and urine 
after kidney injury (17, 18).  The release of TNFα leads to the recruitment of neutrophils 
and other immune cell types to the site of injury (9, 10). 
While most of the mechanisms of injury associated with cisplatin-induced 
nephrotoxicity are tubule and immune-cell focused, subsequent damage to renal 
vasculature via endothelial dysfunction leads to irregular vasoconstriction and further 
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damage to the kidney (1).  In addition, cisplatin is directly toxic to endothelial cells which 
comprise blood vessels in the kidney (1).  The culmination of this multi-faceted injury 
causes loss of blood flow to the kidney, and creates a hypoxic environment which can 
exacerbate stress and cell death within tubular cells (1).  Damage to both the vasculature 
and loss of tubular cells leads to an overall loss of renal tissue, and subsequent loss of 
kidney function.  With cisplatin, this loss of function is severe and occurs over a period of 
only a few days, and in doing so, is classified as acute kidney injury (AKI) (19). 
1.4 Acute Kidney Injury 
Clinically, AKI is diagnosed by measures of serum creatinine (SCr), glomerular 
filtration rate (GFR), and urine output (19, 20).  For diagnosis of cisplatin-induced AKI, 
SCr is commonly used.  According to RIFLE criteria, a patient diagnosed with AKI will 
have a doubling in their baseline SCr levels, or a >50% decrease in GFR (19, 20).  Ten to 
15% of patients with AKI may have severe loss of function requiring dialysis- a costly 
medical treatment that does not repair kidney injury sustained.  Furthermore, AKI has a 
50% mortality rate, and this mortality rate varies based on the cohort of patients being 
studied (21).  For example, the mortality rate from AKI in patients in the ICU is closer to 
80% (22, 23).   
There are many different forms of AKI, and these can be divided into three 
categories: (1) prerenal, (2) intrinsic, and (3) post renal (9).  Cisplatin causes intrinsic 
injury, and cisplatin nephrotoxicity accounts for 19% of the total cases of AKI, making it 
a major health concern (21)  Approximately one third of patients will develop AKI after a 
single dose of cisplatin, and the amount of cisplatin administered, as well as the 
frequency that the dose is given are the two greatest risk factors for developing cisplatin-
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induced AKI (24-26)  Gender (being female), advanced age, smoking, and pre-existing 
renal dysfunction are also contributing factors to increased risk of developing cisplatin-
induced AKI.  These risk factors also contribute to poor long-term outcomes associated 
with cisplatin treatment-namely the development of chronic kidney disease (CKD). 
1.5 Development of CKD after AKI 
Until recently, AKI was thought to be a reversible syndrome, and patients that did not 
require dialysis or die from AKI would have a return to normal kidney function once the 
initial injury was resolved (1).  However, large-scale longitudinal studies from the past 
decade suggest that AKI can result in permanent kidney damage associated with CKD 
(24-26).  Patients with AKI have a ten time greater risk of developing CKD, and this risk 
is further increased with severe AKI, as well as multiple instances of AKI.  Not only have 
studies shown an increased risk for developing CKD after AKI, but experimental data 
have highlighted that AKI can progress to CKD.  In fact, it is estimated that ~20% of all 
patients with AKI will progress to CKD in as little as 18-24 months (27). 
1.6 The Progression of AKI to CKD 
While AKI has been indicated as an independent risk factor for the development of 
CKD, the idea that AKI can cause CKD in humans has been debated due to several 
confounding factors, such as lack of temporal cause/outcome and pre-existing 
comorbidities that may pre-dispose patients to the development of CKD (28).  However, 
both experimental data and human studies indicate that AKI can lead to CKD. Healthy 
patients who develop AKI have abnormal renal function long after the initial AKI insult 
is treated or resolved.  This finding has been recapitulated in two separate studies in 
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young patients (average age 31-32 years old) who were healthy before their AKI (29).  
Furthermore, patients who had severe AKI showed long-term abnormalities in their 
ability to concentrate urine (29).  A case study from Sasaki et al reported on two patients 
who developed CKD after cisplatin treatment (30).  Both patients were treated with 80 
mg/m2 cisplatin for esophageal cancer.  These patients had a spike in their SCr levels that 
required immediate hemodialysis.  Several months later, a kidney biopsy was taken and 
revealed the development of glomerulosclerosis, lymphocyte infiltration into the kidney, 
and interstitial fibrosis (30). 
The interference of other comorbidities contributing to the development of CKD can 
be accounted for by studying pediatric cancer patients (31).  The pediatric cancer 
population is the ideal demographic for studying the development of CKD after cisplatin-
induced AKI.  This population is relatively healthy, and has fewer risk factors than the 
adult population.  Therefore, better conclusions can be made about the true risk of 
developing CKD after cisplatin-induced AKI.  In one study of children that received 
cisplatin for a variety of cancers, approximately 50% showed signs of nephrotoxicity four 
years post-treatment, and 36.4% of these children maintained a decreased GFR indicative 
of CKD (24).  Skinner et al also reported that 11% of children who had received cisplatin 
or carboplatin had decreased GFR ten years post-treatment (32).  Taken together, these 
studies highlight the long-lasting effects on the kidney after cisplatin treatment.  
However, the mechanisms that lead to the development of CKD after are not fully 
understood in humans, and thus animal models have become increasingly important to 
understand this disease progression.        
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Animal studies using ischemia-reperfusion (I/R) injury have been crucial for 
understanding the underlying processes involved in the progression from AKI to CKD (1, 
9).  Ischemia-reperfusion results in an acute but temporary loss of blood flow to the 
kidney, causing high levels of damage.  Studies with this experimental model of injury 
have indicated that there is residual renal structural damage even after the initial AKI is 
no longer detectable by changes in SCr.  Furthermore, these animals often develop 
interstitial fibrosis, with a persistent reduction in capillary density within the kidney (1).  
These processes which remain altered after AKI are known contributors to CKD 
development. 
1.7 Mechanisms of Maladaptive Repair 
After injury occurs to the kidney, the kidney may undergo adaptive repair processes 
that restore kidney function.  This involves the ability of injured tubular cells to 
regenerate, which is mediated by an immune cell response and resolution of 
inflammation that occurs with AKI (1).  While neutrophils are the first immune cell type 
recruited to the site of injury, their role in repair and injury remain unclear.  Shortly after 
recruitment of neutrophils, however, M1 subtype macrophages are recruited to the site of 
injury (9).  M1 macrophages are pro-inflammatory in nature, and amplify initial injury 
(33-35). Over time, these M1 macrophages adopt an M2 phenotype.  M2 macrophages 
are vital for the removal of both dead neutrophils and other cellular debris after initial 
injury, contributing to renal repair.   
Adaptive repair relies on increases in circulating and endogenous compounds that 
promote cell proliferation and resolution of inflammation (1).  M2 macrophages release 
growth factors, fibronectin, and Wnt-7b that aid in tubular repair and subsequent 
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proliferation of tubule cells (35).  Furthermore, damage to vasculature leads to the release 
of heme oxygenase 1 (HO-1), which initiates an anti-inflammatory response (1).  In 
addition to these processes, endothelial repair and regeneration is also important for 
adaptive repair.  However, with I/R injury in rats, there is long-term reduction in 
peritubular capillary density with persistent renal hypoxia, leading to injury progression 
(1).  These data highlight that perhaps there is never full recovery from injury, and 
alludes to the worsening of renal injury leading to fibrosis and CKD even after kidney 
function levels return to baseline.  The mechanisms contributing to the development of 


























Adapted from Ferenbach et al (1) 
Figure 1.1.  Mechanisms of maladaptive repair.  After the kidney is injured, the 
kidney is able to resolve inflammatory processes, and promote tubular proliferation/ 
endothelial cell repair.  However, if injury persists or there are multiple instances of 
injury, tubular epithelial cells are prone to senescence.  In this senescent state, cell 
produce pro-fibrotic growth factors which can stimulate myofibroblast differentiation 
and proliferation, ultimately resulting in fibrosis.  
10 
 
As previously discussed, the risk of developing CKD after AKI in patients increases 
with recurrent episodes of AKI.  Recurrent injury to tubular cells can promote the 
development of fibrosis, indicative of CKD.  Repeated dosing studies with diphtheria 
toxin in mice with tubular epithelial cells expressing the diphtheria toxin receptor indicate 
that injury specific to tubular epithelia results in persistent inflammation, microvascular 
rarefaction, fibrogenesis with subsequent pro-fibrotic growth factor production, and the 
development of glomerulosclerosis (36, 37).  Furthermore, sub-lethal injury to tubular 
cells induces premature cellular senescence and the inability of these cells to proliferate 
and regenerate after injury (36, 37).  Tubular cells in their dedifferentiated, senescent 
state continue to produce pro-fibrotic growth factors, exacerbating damage to the kidney 
vasculature (1).  Production of pro-fibrotic growth factors also stimulates myofibroblast 
differentiation and proliferation, resulting in high levels of collagen production associated 
with fibrosis (1). 
Other perturbations in adaptive repair responses can cause progressive injury.  Of 
note, M1 macrophages may not polarize to M2 with chronic injury, thus prolonging the 
pro-inflammatory response.  Ultimately, maladaptive repair processes lead to the 
development of renal fibrosis and further damage to renal vasculature, causing 
progressive loss of renal function and loss of blood flow- both of which are heavily 
involved in CKD. 
1.8 Chronic Kidney Disease  
Chronic kidney disease is clinically characterized by decreased kidney function as 
measured by SCr or GFR, presence of proteinuria, and presence of albuminuria for more 
than three months (38).  CKD is a slow, progressive disease that is often asymptomatic in 
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its early stages.  However, as the disease progresses, interstitial fibrosis and 
glomerulosclerosis begin to develop leading to a decline in kidney function (38).  As 
interstitial fibrosis worsens, tubule cells in the kidney are separated from peritubular 
capillaries.  This results in a lack of blood flow to the tubule cells, depriving them of 
oxygen and nutrients, while at the same hindering them from excreting toxins and waste 
products out of the cell (38).  Due to the progressive nature of the disease, many patients 
will require dialysis on a regular basis, and these patients are more likely to progress to 
end stage renal disease (ESRD) (27, 38).  Controlling for comorbidities, there are about 
400 deaths per million people from CKD alone (27).  
1.9 Clinical Strategies for Treating Cisplatin-Induced Kidney Injury 
Patients with either AKI or CKD often have increased mortality rates and may require 
dialysis and, unfortunately, there are no options available for the treatment of either 
disease.  The goal for treatment of cisplatin-induced kidney injury would be to protect the 
kidney from injury altogether- highlighting the need for renoprotective therapy options.  
However, only one drug is available for cisplatin-induced nephrotoxicity.  Amifostine 
was first FDA approved as a renoprotective agent in the early 2000s because of its ability 
to inactivate the nephrotoxic metabolites of cisplatin within the cell (39).  In Phase III 
clinical trials in patients with ovarian cancer, amifostine lowered the rate of cisplatin 
nephrotoxicity from 33% to 10% (7, 40).  However, the cisplatin dosing regimen for 
treating ovarian cancers greatly differs from the dosing regimen used to treat other forms 
of cancer.  Patients with ovarian cancer are administered 90-270 mg/m2 of cisplatin once.  
Most solid tumor cancers treated with cisplatin use lower doses of cisplatin given 
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repeatedly.  The use of amifostine with this type of dosing regimen exacerbates 
nephrotoxicity (41).  Due to this, amifostine is rarely used in combination with cisplatin.    
Few interventions are available clinically to protect against the development of AKI. 
As a precaution, patients receive saline infusions prior to cisplatin treatment to protect 
against the development of AKI.  However, even with this precaution in place, 
approximately 30% of patients still develop AKI.  For patients that have increased SCr 
levels during cisplatin treatment, the oncologist has limited options for protecting from 
further injury.  Oncologists may choose to either switch the patient to a less nephrotoxic 
albeit less potent platinum-based therapy (i.e. carboplatin or oxaliplatin), or skip/lower 
the next dose of cisplatin.  Neither of these options are ideal for the treatment of cancer, 
which requires an aggressive therapy for a curative effect. 
1.10 Lack of Therapies for Cisplatin-Induced Kidney Injury 
Although many pharmacological strategies have been indicated as having 
renoprotective potential, few have succeeded in clinical trials (Table 1.1) (42, 43).  This 
may be due to the fact that clinical trials for new AKI therapies usually have low 
enrollment and poor endpoint measures for drug efficacy (44, 45).  Clinical trials for 
experimental AKI therapies have a low enrollment number because many patients with 
AKI have comorbidities (such as pre-existing CKD or diabetes) that can alter their 
outcome to the drug being tested (28, 44).  Without a proper sampling group, the 
statistical power of clinical trials is poor.  In the PICARD study, 30% of patients screened 
for AKI clinical trials had CKD, 29% had diabetes, and many had extrarenal organ failure 
(46).  These comorbidities contribute to failed treatment regimens, especially when the 
endpoint of the clinical trial is mortality. 
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In addition, the endpoint measure for many AKI studies is SCr.  However, SCr is a 
poor biomarker and does not truly reflect kidney function. Serum creatinine levels can be 
affected by age, gender, and muscle mass; therefore even baseline levels are not 
reflective of kidney function (44, 47, 48).  Finally, changes in SCr usually do not occur 
until there is 50% nephron loss- a relatively high level of damage to the kidney.   
Aside from poor clinical trial design, there is a lack of a physiologically relevant 
animal models to study cisplatin-induced AKI.  The commonly used mouse model of 
Table 1.1.  Failed clinical trials for AKI renoprotective strategies.  Although some 
renoprotective therapies have made it to early stage clinical trials, few have advanced 
beyond this point.  
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cisplatin-induced kidney injury consists of administering one, very high dose of cisplatin 
(10-30 mg/kg) that causes mice to die 3-4 days after injection (49-51).  This dosing 
regimen does not take into consideration that patients often receive repeated, lower doses 
of cisplatin to maintain therapeutic efficacy while curtailing nephrotoxic side effects.  
Furthermore, this model does not allow long-term studies of renal outcomes with 
cisplatin pertaining to the development of CKD.  Combined, poor clinical trial design and 
lack of relevant pre-clinical models provide insight into why there are no therapeutic 
options for treatment of cisplatin-induced kidney injury. 
1.11 Current Limitations in the Experimental Model of Cisplatin-Induced AKI 
Addressing the limitations of the established mouse model of cisplatin-induced AKI 
is essential for identifying new therapeutic targets.  In particular, developing a dosing 
regimen that better recapitulates the therapeutic regimen patients receive can provide 
better mechanistic insight into injury associated with repeated dosing of cisplatin.  
Concurrently, including comorbidities such as age and cancer in the mouse model would 
improve the relevancy of the model, as only patients with cancer receive cisplatin, and 
the median age of all cancer diagnoses is 65 years old (52).  
During normal aging, studies in mice and humans have indicated that physiological 
changes in the kidney occur over time, leading to a progressive decline in kidney 
function.  In humans, this process begins around age 30 (53).  In addition, inflammatory 
and immune function within the kidney is altered with aging.  Combined, these changes 
could increase susceptibility to cisplatin-induced AKI.  Furthermore, treatment of cancer 
has improved greatly over the last decade, meaning that there is now a rising population 
of patients who will have to deal with long-term outcomes associated with cisplatin 
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treatment.  Thus, developing a mouse model to combine both a clinically relevant dosing 
regimen of cisplatin and to study the effects cancer and aging may have on altering injury 
outcomes would provide comprehensive insight into cisplatin-induced AKI and its 
progression to CKD.    
1.12 Developing a Clinically Relevant Mouse Model of Cisplatin-Induced Kidney 
Injury 
Several groups have developed more relevant cisplatin dosing regimens in which mice 
are given the drug repeatedly and at lower doses to recapitulate how patients receive 
cisplatin (Table 1.2).  Torres et al demonstrated that administering 15 mg/kg cisplatin, 
followed by a second dose two weeks later, led to changes in kidney function indicative of 
AKI (54).  This loss of kidney function was accompanied by high levels of apoptotic cell 
death, and slight changes to glomerular capsules which correlated to a decrease in GFR.  
However, there was little collagen accumulation, no increase in macrophage activity, and 
no increase in myofibroblast proliferation suggesting no fibrosis was occurring (54).     
Ravichandran et al injected 8-10 week old C57BL6 mice with 10 mg/kg cisplatin once 
a week for four weeks.  At the end of this dosing regimen, there was a significant increase 
in both blood urea nitrogen (BUN) and SCr levels in addition to moderate levels of 
apoptosis and necrosis (55).  Collagen accumulation was present at the endpoint of the four 
week study, but there was no overt fibrosis.  Similarly, Katagiri et al injected 7-8 week old 
C57BL6 mice once a week for three weeks with 10 mg/kg cisplatin.  A week after the final 
dose, there was a significant increase in BUN and SCr (56).  Further analysis showed loss 
of brush border and acute tubular necrosis, which are indicative of tubule damage.  
Furthermore, Katagiri et al. confirmed the presence of fibrosis via Masson’s Trichrome 
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staining and an increase in both Tgfβ and αSma mRNA levels (56).  However, most mice 
were unable to survive the entirety of the dosing, suggesting that the accumulation of 
cisplatin caused severe nephrotoxicity.   
The studies described here highlight that AKI can develop with repeated administration 
of cisplatin, but the ability to use these models to study long-term effects associated with 
the development of CKD after cisplatin-induced AKI are limited by poor survival or lack 
of fibrosis.  To address these limitations, our lab has developed a repeated dosing regimen 
that causes fibrosis with a 100% survival rate (Table 1.2) (50, 51).  This dissertation focuses 
on using this repeated dosing regimen as a basis for building a clinically relevant mouse 














   
Table 1.2.  Experimental, repeated dosing regimens of cisplatin.  Although the 
amount of cisplatin and how often cisplatin is given varies between these models, 




OVERALL GOALS AND SPECIFIC AIMS 
 While the development of therapies for cisplatin-induced kidney injury has been a 
field of study for several decades, there are still no clinically approved agents.  The lack 
of therapies may be due to poor clinical trial design and outcome predictors, as well as a 
need for a more clinically relevant pre-clinical mouse model for testing potential 
renoprotective agents.  The current, experiment mouse model of cisplatin-induced AKI 
consists of injecting mice with one, high dose of cisplatin (10-30 mg/kg) which causes 
mice to become moribund 3-4 days after the initial injection.  Patients receive cisplatin in 
low doses over an extended period of time to avoid nephrotoxicity, and the increased risk 
of mortality associated with it.  Thus, it is crucial to develop a dosing regimen that better 
mimics the dosing regimen patients receive.  In addition, an ideal model of cisplatin-
induced kidney injury would better mimic patient characteristics via examining the 
effects of cancer and aging in the model.   
 The overall goal of this dissertation is to establish a clinically relevant mouse 
model of cisplatin-induced kidney injury that can be used to examine long-term outcomes 
of cisplatin nephrotoxicity.  In addition, this model would be essential for monitoring 
disease progression from AKI to CKD.  The outcomes of this study would aid in 
identifying novel therapeutic targets for the treatment of cisplatin-induced kidney injury.  
The specific aims of this project are as follows: 
Aim 1: Develop a clinically relevant dosing regimen of cisplatin in mice that models 
the progression of cisplatin-induced AKI to CKD. 
 Repeated, low dose cisplatin administration in mice causes interstitial fibrosis, 
which is indicative of CKD.  CKD is a progressive disease with many other pathologies 
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in addition to interstitial fibrosis, including endothelial dysfunction, chronic 
inflammation, and glomerular pathologies.  Mice treated with our repeated cisplatin 
dosing regimen develop the aforementioned pathologies six months post-treatment.  
Thus, we have developed a bona fide model of cisplatin-induced CKD.     
Aim 2: Determine if aging increases susceptibility to AKI/ causes worsened kidney 
injury with the clinically-relevant dosing regimen of cisplatin. 
 It is hypothesized that aging is a risk factor for developing more severe 
nephrotoxicity and exacerbated kidney injury due to physiological changes that occur 
during normal aging.  However, the clinical data to support this hypothesis is limited by 
the fact that older patients that receive cisplatin have comorbidities that may predispose 
them to AKI or CKD.  Animal studies to explore the relationship between aging and 
worsened renal injury from cisplatin are often hindered by the fact that mice used are 
usually extremely old (24 months), while most cancer diagnoses are in middle-aged 
patients (55-65 years old).  To improve on this, we utilized 8 and 40 week old mice, and 
treated them with either the standard or repeated dosing regimen of cisplatin (25 mg/kg 
once or 7 mg/kg once a week for 4 weeks, respectively) to determine the severity of 
cisplatin nephrotoxicity.  Our data indicate that aging does not have a major effect on 
renal injury outcomes, and suggests that the risk of cisplatin-induced kidney injury may 
not be as greatly affected by advanced age as previously believed. 
Aim 3: Increase clinical relevancy of the newly established model of cisplatin-
induced kidney injury by incorporating cancer. 
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 Only patients who have cancer will receive cisplatin, thus incorporating cancer 
into our repeated dosing model of cisplatin is crucial to the clinical validity of our model.  
Furthermore, rates of AKI are higher in cancer patients than in critically ill patients 
without cancer.  Thus, we utilized an inducible, transgenic mouse model of mutant Kras 
lung adenocarcinoma in combination with our repeated dosing regimen of cisplatin. Mice 
with lung adenocarcinoma that received cisplatin had decreased overall survival, earler 
peaks in kidney injury, and worsened renal fibrosis compared to non cancer mice treated 
with the cisplatin.  Western blot analysis indicated an increase in EGFR protein levels 
and subsequent differential activation of EGFR-mediated signaling pathways in cancer 
mice treated with cisplatin.  EGFR is highly involved in kidney injury, and is a major 
contributor to renal fibrosis.  Thus, we hypothesized that blocking EGFR activation with 
erlotinib, an FDA-approved EGFR inhibitor, would protect against the development of 
renal fibrosis.   Combinatorial treatment of both non cancer and cancer with cisplatin + 
erlotinib caused severe AKI.  Thus, erlotinib is not a viable renoprotective agent in our 









SUB-CLINICAL KIDNEY INJURY INDUCED BY REPEATED CISPLATIN 
ADMINISTRATION RESULTS IN PROGRESSIVE CHRONIC KIDNEY DISEASE 
 
INTRODUCTION 
Patients with AKI are ten times more likely to develop CKD than patients without 
AKI (25, 57).  This risk further increases with the severity of AKI, as well as having 
repeated episodes of injury (1, 26, 29, 58).  However, whether or not AKI progresses to 
CKD is still controversial.  Many of the same processes involved in adaptive repair after 
kidney injury can contribute to worsening injury if these processes are sustained for long 
periods of time.  These processes have been termed “mechanisms of maladaptive repair” 
(Figure 1.1) (1).  Most studies of maladaptive repair have been performed with the I/R 
model of AKI, which focuses more on the vascular injury that occurs with AKI.  
Therefore, there is a need for a cisplatin model to better understand how these 
mechanisms of maladaptive repair are important for the progression of cisplatin-induced 
AKI to CKD. 
Our group and others have shown that the repeated administration of low dose 
cisplatin causes interstitial fibrosis, an endpoint pathology indicative of CKD (50, 51, 54-
56, 59).  The development of fibrosis in these models is accompanied with little to no cell 
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death.  Thus, targeting apoptotic and necrotic signaling pathways may be a poor 
therapeutic option for cisplatin-induced kidney injury (60).  Furthermore, these studies 
highlight that targeting fibrotic signaling pathways may be a better therapeutic option for 
injury caused by cisplatin. While fibrosis is a hallmark pathology of CKD, CKD is a 
progressive, multi-faceted disease with many different pathologies including 
glomerulosclerosis, endothelial dysfunction and damage, and chronic inflammation (1, 
38, 61).  For cisplatin-induced kidney injury, there is a lack of knowledge about which 
mechanisms may contribute to the aforementioned pathologies associated with CKD.  
Identifying these mechanisms would aid in the development of therapies to target the 
development and progression of CKD after cisplatin treatment. 
We have previously shown that mice develop interstitial fibrosis and are able to 
survive the entirety of our repeated dosing regimen (7 mg/kg cisplatin once a week for 4 
weeks) (50).  Building upon this work we hypothesized that, due to the progressive nature 
of CKD, glomerular pathologies and endothelial damage may only be seen at a later time 
point with our model.  To this end, we treated mice with our repeated dosing regimen of 
cisplatin and examined long-term kidney outcomes at the 6 month time point.  To gain 
insight into components of fibrotic signaling pathways that may be changing early on 
with repeated cisplatin administration, we also treated mice with only 2 doses of cisplatin 
and euthanized them at Day 10.  
After Dose 2 of cisplatin, there was subtle inflammation, but no overt changes in 
kidney function, tubular damage, and no interstitial fibrosis.  While there was only a 
subtle change in kidney function after treating mice with 4 doses of cisplatin at Day 24, 
there was a significant increase in inflammation, endothelial dysfunction, and the 
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development of interstitial fibrosis.  Six months post cisplatin treatment, inflammation 
and interstitial fibrosis were worse.  At this time point, mice developed glomerular 
pathologies, and there was development of atherosclerotic lesions in the kidneys as 
evidenced by increased CD31 expression in the medulla.  These data indicate that the 
nephrotoxic effects of repeated cisplatin dosing are long-lasting, leading to the 
maintenance of maladaptive repair processes including chronic inflammation, worsened 
interstitial fibrosis, and glomerular/endothelial changes contributing to decreased kidney 
function. 
MATERIALS AND METHODS 
Animals.  For age out studies, 8 week old male FVB/n mice (001800, The Jackson 
Laboratory, Bar Harbor, ME) were maintained under standard laboratory conditions.  All 
animals were housed under a 12:12 hour light-dark cycle and provided food and water ad 
libitum.  Animal procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at University of Louisville, and followed the appropriate guidelines 
set forth by the American Veterinary Medical Association.  Pharmaceutical grade 
cisplatin was purchased from the University of Louisville Hospital Pharmacy (1 mg/ml in 
normal saline, Teva Pharmaceuticals).  Mice were intraperitoneally injected at 8:00 a.m. 
with either saline vehicle (0.9% saline in ddH2O) or cisplatin (7 mg/kg) once a week for 
either two or four doses (Figure 2.1).  At Day 10 (3 days after Dose 2), a cohort of saline 
vehicle and cisplatin treated mice were euthanized.  At Day 24 (3 days after Dose 4), a 
second cohort of saline vehicle and cisplatin treated mice were euthanized.  A third 
cohort of mice received 4 doses of saline vehicle or cisplatin, and were sacrificed 6 
months after the final dose.  For this experiment, mice were monitored for weight loss or 
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high levels of discomfort/stress on a daily basis, and were euthanized if weight loss was 
greater than 20%. 
Figure 2.1.  Repeated dosing regimen.  8 wk old, male FVB mice were treated with 
either 2 doses saline vehicle or cisplatin (7 mg/kg) and euthanized at Day 10.  Another 
group was treated with either 4 doses of saline vehicle or cisplatin (7 mg/kg) and 




Sample collection and storage.  Urine was collected prior to euthanasia and stored at -
80°C.  Upon euthanasia, blood was collected and placed on ice.  Plasma was then 
prepared by spinning blood samples at 10,000xg for 10 minutes at 4°C, and stored at -
80°C.  Kidneys were removed, sliced, and tissue was allocated for appropriate use 
(Figure 2.2).  Tissue for protein, RNA, and all extra kidney tissue were flash-frozen in 
liquid nitrogen, and samples for histology/immunohistochemistry were fixed in 10% 
neutral buffered formalin. 
 
   
 
 
BUN determination.  Blood urea nitrogen (BUN) levels in plasma were determined after 
Dose 2, 4, and after 6 month age out using a kit from AMS Diagnostics (80146, AMS 
Diagnostics, Weston, FLA) per the manufacturer’s instructions. 
ELISAs.  ELISAs for neutrophil gelatinase associated lipocalin (NGAL; DY1857, R&D 
Systems, Minneapolis, MN) and albuminuria (1011, Exocell, Philadelphia, PA) were 
Figure 2.2.  Allocation of kidney tissue.  Upon euthanasia, the right kidney was 
removed, and tissue was allocated for protein isolation, RNA isolation, and paraffin 
embedding as pictured.  The left kidney and remaining tissue from the right kidney 




done on urine samples after Dose 2, 4, and after 6 month age out following 
manufacturers’ protocols. 
Gene expression.  Total RNA was isolated using the EZNA Total RNA Kit (R6834-02, 
Omega, Weston, FLA) per manufacturer’s protocol.  cDNA was made from 1μg of total 
RNA using High-Capacity Reverse Transcriptase (4368814, Life Technologies, Grand 
Island, NY) following manufacturer’s instructions.  Gene-specific cDNA was quantified 
using real-time QRTPCR and either pre-designed Taqman assays, or self-designed Sybr 
assays.  The following pre-designed primers were used: (Life Technologies, Grand 
Island, NY) Tumor necrosis factor alpha [Tnfα (Mm00443258_m1)], interleukin-6 [Il-6 
(Mm00446190_m1)], [Cxcl1 (Mm04207460_m1)], monocyte chemoattractant protein-1 
[Mcp-1 (Mm00441242_m1)], connective tissue growth factor [ Ctgf 
(Mm01192932_m1)], collagen subtype 1a1 [Col1a1 (Mm00801666_m1)], arginase-1 
[Arg-1 (Mm00475991_m1)] and β2 microglobulin [B2m (Mm00437762_m1)].  The 
following gene primers were self-designed: inducible nitrogen oxide synthase (Inos), 
transforming growth factor beta 1 (Tgfβ1), fibronectin 1 (Fn1), Endothelin-1, TIMP 
metallopeptidase inhibitor 1 (Timp-1), vascular cell adhesion molecule 1 (Vcam-1), and 
intercellular adhesion molecule 1 (Icam-1).  Primers were used in combination with 
either iTaq Universal Probes Supermix (172-5134, BioRad, Hercules, CA) or iTaq 
Universal Sybr Green Supermix (172-5124, BioRad, Hercules, CA).   
Preparation of kidney sections for histology and immunohistochemistry.  After 
fixation in 10% neutral buffered formalin for 48 hours, kidney samples were stored in 
75% ethanol for at least one hour.  Samples were then prepared for paraffin embedding 
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(Table 2.1).  After embedding, kidney sections were cut 5 microns thick on a microtome, 




Histology.  Kidney sections (5 microns thick) were stained either with Mayer’s 
hematoxylin (MHS32-1L, Sigma) and alcoholic eosin (HT110116, Sigma) (Table 2.2), or 
Periodic acid-Schiff stain [PAS; (Periodic acid solution: 395132-1L, Sigma) (Schiff’s 
reagent: 3952016-1L, Sigma)] (Table 2.3).  Pathological analysis was performed by Dr. 
Judit Megyesi, a mouse renal pathologist.  Measures of both tubular and glomerular 
damage were evaluated on a scale from 0 to 4, which ranged from not present (0) to mild 
(1), moderate (2), severe (3), and very severe (4).   
Table 2.1.  Preparation of tissue for paraffin embedding.  Briefly, samples 
were run through an ethanol gradient, followed by Histoclear and Paraplast 







Immunohistochemistry.  For alpha smooth muscle actin (αSMA) 
immunohistochemistry (IHC), kidney sections (5 microns thick) were rehydrated with 
Histoclear (HS-200, National Diagnostics) followed by an ethanol gradient.  Sodium 
citrate buffer (pH 6.0) was used for antigen retrieval.  Antigen retrieval was performed in 
a vegetable steamer for 75 minutes, and slides were cooled at room temperature (RT) for 
Table 2.2.  Hematoxylin and Eosin staining.  Protocol for H&E staining. 
 
Table 2.3.  Periodic acid-Schiff staining.  Protocol for PAS staining. 
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60 minutes.  Slides were then rinsed in dH2O for five minutes.  Endogenous peroxidases 
were blocked with 3% hydrogen peroxide for 10 minutes, and slides were washed twice 
in PBS for 5 minutes each.  Slides were then blocked for avidin for 10 minutes, washed 
in PBS for five minutes, and then blocked for biotin for 10 minutes (SP2001, Dako, 
Burlingame, CA), followed by another PBS wash.  Slides were further blocked in 5% 
normal goat serum in PBS for 1 hour at RT (PK-7100, Vector Laboratories).  Alpha 
smooth muscle actin primary antibody (ab5694, Abcam) was diluted 1:400 in antibody 
diluent [(0.5 μg/ml), 8112L, Cell Signaling] and added to sections.  Slides were then 
coverslipped and incubated with the primary antibody overnight at 4°C.  The following 
morning, slides were rinsed 3 times for 5 minutes each with PBS.  Biotinylated goat anti-
rabbit IgG antibody [(1:25000), PK-7100, Vector Laboratories] was added to slides and 
incubated for 30 minutes at RT.  Slides were then rinsed 2 times for 5 minutes in PBS 
before Vector ABC reagent was added (PK-7100, Vector Laboratories) for 30 minutes at 
RT.  Slides were rinsed two times for 5 minutes with PBS.  NovaRed peroxidase 
substrate solution (SK-4800, Vector Laboratories) was added to slides for seven minutes, 
and slides were rinsed in dH2O for 5 minutes.  Slides were counterstained with Modified 
Mayer’s Hematoxylin (72804, Thermo-Scientific) for 30 seconds, and then rinsed with 
dH2O until water ran clear.   Bluing solution (1.5% ammonium hydroxide in 70% 
ethanol) was added to slides for 30 seconds, and then rinsed in dH2O for 5 minutes.  
Following this step, slides were dehydrated in the ethanol gradient to Histoclear, fixed 
with Permount (SP15-100, Fisher), and coverslipped.  Images of whole kidney sections 
were taken using the Aperio Slide Scanner.  
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 For CD31 IHC, kidney sections were rehydrated as described for αSMA IHC. 
Sodium citrate buffer (pH 6.0) was used for antigen retrieval for 40 minutes at 95°C.   
Slides were serum blocked with goat serum for 2 hours at RT (PK-7100, Vector 
Laboratories) and washed twice with TBS 0.01% Triton X-100 for 5 minutes.  Slides 
were then blocked for avidin and biotin as described for αSMA IHC.  CD31 antibody 
(ab124431, Abcam) was added to slides at 1:500 dilution in TBS with 1% BSA.  TBS 
with 1% BSA was added to negative controls.  Slides were coverslipped and allowed to 
incubate overnight at 4°C.  The following morning, slides were washed twice with TBS 
0.01% Triton X-100 for 5 minutes.  Endogenous peroxidases were blocked with 3% 
hydrogen peroxide for 30 minutes, and slides were washed with TBS 0.01% Triton X-
100.  Biotinylated goat anti-rabbit IgG antibody in TBS with 1% BSA [(1:25000), PK-
7100, Vector Laboratories] was added to slides and incubated for 30 minutes at RT.  
Slides were then rinsed 2 times with TBS 0.01% Triton X-100 for 5 minutes before 
Vector ABC reagent was added (PK-7100, Vector Laboratories) for 30 minutes at room 
temperature.  Slides were then rinsed two times for 5 minutes with TBS 0.01% Triton X-
100.  NovaRed peroxidase substrate solution (SK-4800, Vector Laboratories) was added 
to slides for 5 minutes, and then slides were rinsed in dH2O for 5 minutes.  Slides were 
counterstained with Modified Mayer’s Hematoxylin and processed as described for 
αSMA IHC.  
For F4/80 IHC, kidney sections (5 microns thick) were rehydrated with Histoclear 
followed by an ethanol gradient.  Target retrieval solution (S1699, Dako) was diluted 
1:10 in ddH2O, and slides were incubated in antigen retrieval solution at 72°C overnight.  
The next morning, slides were washed once in TBS for 5 minutes.  Slides were then 
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blocked with hydrogen peroxide, avidin, and biotin as described above for αSMA IHC, 
but using TBS for washes.  Slides were then washed with TBS 0.01% Triton X-100 for 5 
minutes before blocking with 10% normal goat serum (31873, Invitrogen) in TBS 0.01% 
Triton X-100 for 30 minutes.  Primary F4/80 antibody (ab16911, Abcam) was added at a 
1:50 dilution in 10% normal goat serum.  Slides were coverslipped and incubated at RT 
for 2 hours.  Slides were then washed with TBS 0.01% Triton X-100 twice for 5 minutes.  
Biotinylated rat 2° antibody (BA-9401, Vector) was added to all sections and incubated 
for 15 minutes, followed by two washes with TBS for 5 minutes each.  ABC reagent (PK-
6104, Vectastain) was added for 30 minutes, and then slides were washed with TBS twice 
for 5 minutes each.  DAB substrate solution (E885-200ml, Amresco) was added to slides 
at RT for approximately 10 minutes.  Slides were then counterstained, mounted, and 
imaged as described for αSMA IHC.  
Sirius red/ fast green staining for total collagen.  Kidney sections (5 microns thick) 
were rehydrated in Histoclear followed by an ethanol gradient.  Slides were then dipped 
in a Coplin jar containing PBS with 0.1% Tween 20 (PBST) ten times, and this was 
followed by a 5 minute wash with PBST.  Slides were then washed with distilled water 
twice for 5 minutes, and incubated in Sirius red/fast green stain [0.1% sirius red (sirius 
red/direct red 80, 365548, Sigma)  and 0.1% fast green (fast green FCF, F7258, Sigma) in 
saturated picric acid (5860-32, Ricca Chemicals, Arlington, TX)] for 30 minutes in the 
dark.  Slides were then washed with 5% glacial acetic acid water until water was clear.  
Slides were dehydrated through the ethanol gradient, followed by Histoclear before slides 
were mounted with Permount and coverslipped.  Images of whole kidney were taken 
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using Aperio Slide Scanner and optical density of Sirius red was quantified using Fiji-
Image J and the following equation: OD=log (maximum intensity/mean intensity). 
Statistical analysis.  Data are expressed as means ±SEM for all experiments.  Multiple 
comparisons of normally distributed data sets were analyzed by two way ANOVA, as 
appropriate, and group means were compared using Tukey posttests.  The criteria for 
statistical differences were: *P< 0.05, **P< 0.01, ***P< 0.001, and ****P< 0.0001.   
RESULTS 
Kidney injury is detectable after Dose 2 of cisplatin, and kidney function continues 
to decline 6 months post cisplatin treatment.  Mice were treated with either 2 doses or 
4 doses of saline or cisplatin (7 mg/kg) and euthanized 72 hours after the final dose.  
Another group of mice was treated with 4 doses of saline or cisplatin (7 mg/kg) and aged 
for 6 months.  BUN and albuminuria are common measures of kidney function, and 
NGAL is a FDA-approved urinary biomarker for kidney injury (19, 20, 62, 63).  BUN 
was slightly elevated D4 (Dose 4).  BUN was significantly increased 6 months post 
cisplatin treatment (6 mo. post CDDP) (Fig 2.3A).  Albuminuria was elevated at D2 and 
D4 of cisplatin, but returned to baseline 6 mo. post CDDP (Fig 2.3B).  NGAL was 
slightly elevated after Dose 2 (D2), but significantly increased after D4. NGAL levels 
were not elevated 6 mo. post CDDP (Fig 2.3C).  Taken together, these data indicate that 
mice develop albuminuria after D2, but albuminuria is no longer detectable 6 mo. post 
CDDP.  In comparison, significant changes in BUN do not occur until 6 mo. post CDDP, 
indicating a progressive and permanent loss of kidney function even when injury, as 













Figure 2.3. Markers of kidney function and injury during and after repeated 
cisplatin treatment.  8 wk old FVB mice were treated with either saline vehicle or 
cisplatin (7 mg/kg) once a week for two weeks and euthanized 3 days after Dose 2.  
Another group was treated with either saline vehicle or cisplatin (7 mg/kg) once a 
week for four weeks and euthanized 3 days after Dose 4, or aged for 6 months 
following treatment (6 mo. post CDDP).  (A) BUN measured in plasma.  (B) 
Albuminuria measured in urine.  (C) NGAL measured in urine.    Data are expressed 
as mean ± SEM; n=5-10.  Statistical significance was determined by Two-Way 




Repeated cisplatin administration causes tubular injury that is still present 6 
months post-treatment.  Cisplatin-induced AKI results in proximal tubule cell damage, 
and we have previously shown that many of the same types of tubular damage occur with 
repeated cisplatin treatment (9, 10, 14, 15).  Tubular dilation was present after D4, and 
tubules remained dilated 6 mo. post CDDP (Fig 2.4A).  There was a slight loss of brush 
borders after D2, but the severity increased after D4 and damage remained 6 mo. post 
CDDP (Fig 2.4B).  Tubular degeneration occurred after D4 and was still present 6 mo. 
post CDDP (Fig 2.4C).  Severity of tubular cast formation was high after D4 and 6 mo. 
post CDDP (Fig 2.4D).  Interestingly, there was no tubular necrosis with cisplatin 
treatment (Fig 2.4E).  While there was a slight increase in inflammatory cell infiltration 
after both D2 and D4, there was a significant increase in inflammatory cell infiltration 6 
mo. post CDDP (Fig 2.4F).  There was also a significant increase in distal tubule damage 
6 mo. post CDDP (Fig 2.4G).  Taken together, these data indicate that severe tubular 
injury does not occur until after D4 of cisplatin, and that inflammation and distal damage 














Figure 2.4.  Tubular injury during and after repeated cisplatin treatment.  8 wk 
old FVB mice were treated with either saline vehicle or cisplatin (7 mg/kg) once a 
week for two weeks and euthanized 3 days after Dose 2.  Another group was treated 
with either saline vehicle or cisplatin (7 mg/kg) once a week for four weeks and 
euthanized 3 days after Dose 4, or allowed to age for 6 months following treatment 
(6 mo. post CDDP).  Severity of (A) tubular dilation, (B) loss of brush border, (C) 
tubular degeneration, (D) tubular casts, (E) tubular necrosis, (F) inflammation, and 
(G) distal damage was determined by a renal pathologist.  Data are expressed as 
mean ± SEM; n=5-7.  Statistical significance was determined by Two-Way ANOVA 
followed by Tukey post-test.  *P<0.05, ** P<0.01, ***P< 0.001, and ****P<0.0001. 
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Inflammatory cytokine and chemokine levels are altered with repeated cisplatin 
treatment and after 6 month age out.  Inflammation is one of the hallmarks of AKI, 
and chronic inflammation contributes to renal fibrosis (1, 9, 10, 15, 64-66).  Thus, we 
wanted to determine levels of disease-related inflammatory cytokines and chemokines.  
TNFα is the major mediator of inflammation in cisplatin-induced AKI (17, 67).  Tnfα 
mRNA levels were elevated 2-fold after D2, and levels were significantly increased at D4 
(Fig 2.5A).  Tnfα levels remained significantly elevated 6 mo. post CDDP (Fig 2.5A).  Il6 
increased at D2 and remained elevated after D4 (Fig 2.5B).  6 mo. post CDDP, Il6 levels 
increased significantly (Fig 2.5B).  Mcp-1, a chemokine for monocyte recruitment, 
increased slightly after D2, and was elevated 3-fold at D4 and 6 mo. post CDDP (Fig 
2.5C).  Cxcl1, a chemokine for neutrophil recruitment, increased 5-fold after D2, and was 
significantly increased at D4 (Fig 2.5D).  6 mo. post CDDP, Cxcl1 levels were elevated 
7-fold (Fig 2.5D).  These data indicate that inflammatory cytokine and chemokine levels 
increase with each dose of cisplatin examined in this study, and remain elevated after 




















Figure 2.5.  Inflammatory cytokine and chemokine levels during and after 
repeated cisplatin treatment.  8 wk old FVB mice were treated with either saline 
vehicle or cisplatin (7 mg/kg) once a week for two weeks and euthanized 3 days 
after Dose 2.  Another group was treated with either saline vehicle or cisplatin (7 
mg/kg) once a week for four weeks and euthanized 3 days after Dose 4, or allowed 
to age for 6 months following treatment (6 mo. post CDDP).  Levels of (A) Tnfα, (B) 
Il6, (C) Mcp-1, and (D) Cxcl1 were measured in the kidney cortex via real-time 
QRTPCR. Data are expressed as mean ± SEM; n=5-10.  Statistical significance was 





Repeated cisplatin administration causes an increase in M2 macrophages.  
Macrophages mediate kidney injury (1, 10, 68, 69).  With AKI, M1 macrophages are pro-
inflammatory, while M2 macrophages are anti-inflammatory, although the roles of these 
macrophage subtypes are less clearly defined in fibrogenesis and CKD pathogenesis (1, 
34, 68-70).  Thus, we wanted to determine the presence of macrophages in our model, as 
well as subtypes of macrophages.  F4/80 IHC for macrophages indicated an increase in 
total macrophages after D4 (Fig 2.6A).  Six mo. post CDDP, more macrophages were 
present (Fig 2.6A).  Inos is a marker of M1 macrophages (71, 72). Levels of Inos did not 
change with cisplatin treatment (Fig 2.6B).  Arg-1, a marker of M2 macrophages, 
increased after D4 (Fig 2.6C) (71, 72).  Six mo. post CDDP treatment, Arg-1 levels were 
still elevated (Fig 2.6C).  These data indicate an increase in macrophages in the kidney 























Figure 2.6. Total macrophages and macrophage subtypes during and after 
repeated cisplatin treatment.  8 wk old FVB mice were treated with either saline 
vehicle or cisplatin (7 mg/kg) once a week for two weeks and euthanized 3 days after 
Dose 2.  Another group was treated with either saline vehicle or cisplatin (7 mg/kg) 
once a week for four weeks and euthanized 3 days after Dose 4, or allowed to age for 
6 months following treatment (6 mo. post CDDP).  (A) F4/80 IHC staining for total 
macrophages. Levels of (B) Inos and (C) Arg-1 were measured in the kidney cortex 




Repeated cisplatin administration causes chronic pro-fibrotic growth factor 
production.  When proximal tubules are injured, they produce growth factors that aid in 
adaptive repair.  However, repeated injury causes proximal tubules to become senescent, 
leading to the prolonged production of growth factors.  Pro-fibrotic factors like TGFβ and 
CTGF contribute to the development and maintenance of fibrosis (1, 36, 37).  Tgfb1 
levels significantly increased after D4 and remained elevated 6 mo. post CDDP (Fig 
2.7A).  Ctgf increased 2-fold after D4, and remained elevated 6 mo. post CDDP (Fig 
2.7B).  These data indicate that there is continued production of TGFβ and CTGF even 



































Figure 2.7.  Pro-fibrotic growth factor production during and after repeated 
cisplatin treatment.  8 wk old FVB mice were treated with either saline vehicle or 
cisplatin (7 mg/kg) once a week for two weeks and euthanized 3 days after Dose 2.  
Another group was treated with either saline vehicle or cisplatin (7 mg/kg) once a 
week for four weeks and euthanized 3 days after Dose 4, or allowed to age for 6 
months following treatment (6 mo. post CDDP). Levels of (A) Tgfb1 and (B) Ctgf 
were measured in the kidney cortex via real-time QRTPCR. Data are expressed as 
mean ± SEM; n=5-10. Statistical significance was determined by Two-Way 
ANOVA followed by Tukey post-test.  *P<0.05, **P<0.01 
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Interstitial fibrosis develops with repeated cisplatin treatment and worsens 6 
months post cisplatin treatment.  The development of interstitial fibrosis is a hallmark 
of CKD, and fibrosis is progressive (1, 73).  After D4, interstitial fibrosis was present and 
severity increased 6 mo. post CDDP (Fig 2.8A).  Fibrosis is marked by an increase in 
both collagen and fibronectin, components of the extracellular matrix (ECM).  In 
addition, myofibroblasts, which deposit collagen, proliferate during fibrogenesis.  
Myofibroblasts can be detected by αSMA expression, and αSMA IHC indicated an 
increase in myofibroblasts after D4 (Fig 2.8B) (74).  Six mo. post CDDP, there were 
more αSMA positive myofibroblasts (Fig 2.8B).  There was no change in total collagen 
levels after D2, but there was a significant increase after D4 (Fig 2.8C).  Levels of total 
collagen remained elevated 6 mo. post CDDP (Fig 2.8C).  To further confirm the 
presence of fibrosis, Col1a1 levels were not elevated after D2 of cisplatin, but increased 
3-fold after D4 and remained elevated 6 mo. post CDDP (Fig 2.8D).  Fibronectin levels 
increased only after D4, and remained elevated 2-fold 6 mo. post CDDP (Fig 2.8D).  
Thus, data indicate that fibrosis only develops after four doses of cisplatin, and that 







































Figure 2.8. Development of interstitial fibrosis during and after repeated 
cisplatin treatment.  8 wk old FVB mice were treated with either saline vehicle or 
cisplatin (7 mg/kg) once a week for two weeks and euthanized 3 days after Dose 2.  
Another group was treated with either saline vehicle or cisplatin (7 mg/kg) once a 
week for four weeks and euthanized 3 days after Dose 4, or allowed to age for 6 
months following treatment (6 mo. post CDDP).  (A) Interstitial fibrosis levels 
determined by a renal pathologist. (B) Presence of myofibroblasts determined by 
αSMA IHC.  (C) Levels of total collagen determined by SR/FG and optical density 
quantification of Sirius red staining.  Levels of (D) Col1a1 and (E) Fn1 measured in 
kidney cortex via real-time QRTPCR. Data are expressed as mean ± SEM; n=5-10. 
Statistical significance was determined by two-way ANOVA followed by Tukey post-




Glomerular damage occurs 6 months post cisplatin treatment.  CKD is associated 
with damage to glomeruli, ultimately resulting in decreased GFR (38, 61, 73).  Renal 
pathology indicated there was mesangial hypercellularity after D2 and D4 of cisplatin 
(Fig 2.9A).  Interestingly, both saline and cisplatin-treated mice showed increased 
mesangial hypercellularity in glomeruli 6 mo. post CDDP (Fig 2.9A).  Six mo. post 
CDDP, there was also a significant increase in periglomerular fibrosis and thickening of 
the glomerular basement membrane (Fig 2.9B,C).  Taken together, these data indicate 
that most glomerular changes occur 6 mo. post CDDP treatment, which may contribute to 

















Figure 2.9.  Indices of glomerular damage during and after repeated cisplatin 
treatment.  8 wk old FVB mice were treated with either saline vehicle or cisplatin (7 
mg/kg) once a week for two weeks and euthanized 3 days after dose 2.  Another group 
was treated with either saline vehicle or cisplatin (7 mg/kg) once a week for four 
weeks and euthanized 3 days after dose 4, or allowed to age for 6 months following 
treatment (6 mo. post CDDP).  Severity of (A) mesangial hypercellularity, (B) 
periglomerular fibrosis, and (C) thickening of basement membrane was determined by 
a renal pathologist.  Data are expressed as mean ± SEM; n=5-7. Statistical 





Repeated administration of cisplatin causes endothelial dysfunction that is 
maintained 6 months post-treatment.  Endothelial dysfunction and subsequent 
endothelial cell damage are major components of CKD.  Endothelial dysfunction is 
marked by increased production of vasoconstrictors (3,12).  During endothelial 
dysfunction, inflammatory processes are dysregulated, and levels of adhesion molecules 
are elevated to promote adhesion of leukocytes to endothelial surfaces.  Endothelin-1 is a 
potent vasoconstrictor involved in the regulation of endothelial cells that increases during 
early endothelial dysfunction (75-78).  Endothelin-1 significantly increased after D4, and 
remained elevated 6 mo. post CDDP (Fig 2.10A).  Vcam-1 and Icam-1 levels were 
slightly elevated after D2, but significantly increased after D4 (Fig 2.10B,C).  Levels of 
Vcam-1 and Icam-1 remained slightly elevated 6 mo. post CDDP (Fig 2.10B,C).  In 
addition, Timp-1 levels increased after D4 and remained elevated 6 mo. post CDDP (Fig 
2.10D). 
CD31 is highly expressed in endothelial cells, and is used as a marker of 
angiogenesis during atherosclerotic processes (79).  CD31 IHC staining revealed no 
detectable changes in CD31 in the cortex or medulla after D2 or D4 (Fig 2.10E).  
However, there was an increase in CD31 staining in the medulla 6 mo. post CDDP (Fig 
2.10E).  These data indicate that endothelial dysfunction occurs after D2 of cisplatin, 
worsens after D4, and persists 6 mo. post CDDP.  In addition, increased CD31 positivity 
6 mo. post CDDP indicates potential angiogenesis associated with the development of 

































Figure 2.10.  Markers of endothelial dysfunction and damage during and after 
repeated cisplatin treatment.  8 wk old FVB mice were treated with either saline 
vehicle or cisplatin (7 mg/kg) once a week for two weeks and euthanized 3 days after 
Dose 2.  Another group was treated with either saline vehicle or cisplatin (7 mg/kg) 
once a week for four weeks and euthanized 3 days after Dose 4 or allowed to age for 6 
months following treatment (6 mo. post CDDP). Levels of (A) Endothelin-1, (B) 
Vcam-1, (C) Icam-1, and (D) Timp-1 were measured in kidney via QRTPCR. (E) 
CD31 IHC stain for endothelial cell damage in cortex and medulla.   Data are 
expressed as mean ± SEM; n=5-10. Data are expressed as mean ± SEM; n=5-10. 
Statistical significance was determined by two-way ANOVA followed by Tukey post-




By 2020, there will be 15 million new cases of cancer per year worldwide (80). 
Approximately one fifth of patients will receive cisplatin as part of their therapeutic 
regimen.  While it is well established that patients with AKI are at greater risk for 
developing CKD, the novel finding of our study is that mild injury caused by repeated 
low dosing of cisplatin, that does not meet the clinical criteria for AKI, can progress to 
CKD.  Clinically, there is no stringent definition for AKI, but commonly used RIFLE 
criteria define AKI as a doubling in SCr, and 30% of patients that receive cisplatin will 
develop AKI according to this definition (19, 81, 82).   However, little is known as to 
whether the 70% who do not develop clinical AKI are also at risk for poor, long-term 
outcomes including increased mortality risk, development of CKD, or development of 
end stage renal disease (ESRD) (24-26, 83).  In meta-analyses by Chertow et al. and 
Coca et al., some cohorts included in these studies defined AKI as a 25% increase in SCr 
(25, 83).  Even with this mildest form of AKI, there was a 70% increase in mortality risk 
(25, 84).   
SCr is a poor marker for defining AKI, and does not accurately reflect true renal 
function as measures are affected by age, gender, protein intake, and drug metabolism 
(85).  Furthermore, changes in SCr do not occur until there is 50% or greater loss of 
nephrons (86).  Our model supports the notion that even without meeting the clinical 
definition of AKI, kidney injury does occur and it leads to poor long-term outcomes.  
After two doses of cisplatin, we saw tubular pathologies indicative of acute tubular 
injury, although there was no change in BUN levels.  However, there was a 26% increase 
in BUN after Dose 4 of cisplatin, and tubular dilation, loss of brush border, tubular 
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degeneration, and tubular cast formation were more severe-indicating a mild AKI 
phenotype.  Having ways to detect kidney injury before SCr changes is a clinical 
challenge and there are few biomarkers available for accurately measuring kidney 
damage.  We believe our model presents the novel opportunity to identify pathologies 
and their contributing mechanisms that occur early on with cisplatin-induced kidney 
injury, and in doing so, will aid in the identification of more reliable and accurate 
biomarkers for both AKI and CKD.  In turn, this may provide clearer, more stringent 
endpoints for clinical trial design.                
As previously discussed, clinically relevant repeated, low dose cisplatin in vivo 
models have been developed (50, 51, 54-56).  However, our study is the first to look at 
long-term effects post cisplatin treatment and to show that bona fide CKD can result from 
repeated cisplatin administration.  FVB/n mice treated with cisplatin have worsened 
chronic inflammation, and progressive interstitial fibrosis in the kidney 6 months post-
treatment (Table 2.4). These mice also had endothelial dysfunction and glomerular 
pathologies secondary to tubular injury.  This ultimately culminated in a significant 
decline in kidney function, indicative of CKD. 
Of interest, while total inflammation increased 6 months post cisplatin treatment, 
the only cytokine to increase in this same manner was IL6.  IL6 is expressed by 
podocytes, tubular epithelial cells, and mesangial cells under normal physiological 
conditions (76).  IL6 enhances the response of injured tubular cells to pro-fibrotic stimuli 
(87).  Furthermore, high circulating levels of IL6 are commonly found in ESRD patient, 
and Zhang et al. have also shown that IL6 levels increase in the kidneys of patients with 
CKD (88).  IL6 activation can also lead to the expression of fibrotic genes and 
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endothelin-1, indicating the role of IL6 as a major driver of CKD (88).  In addition, 
pathological levels of IL6 are highly associated with increased macrophages in the 
kidney, as IL6 is responsible for switching dendritic cells to a macrophage phenotype 
(76). In our model, Il6 mRNA levels in the kidney were highest in mice 6 months post 
cisplatin treatment, and this correlated with high F4/80 positive staining for macrophages.  
The robust increase in Il6 levels at this time point may be indicative of progressive CKD.  
This provides evidence that IL6 may be a potential therapeutic target for preventing the 
development and progression of CKD after cisplatin-induced kidney injury, as inhibition 
or depletion would affect a number of contributing pathways.  Indeed, in a model of acute 
peritoneal inflammation, IL6-/- mice did not develop fibrosis (64).  
An important finding of this study was that total macrophages increased after 4 
doses of cisplatin, and more macrophages were detected 6 months post cisplatin 
treatment.  Macrophages are key mediators of AKI, and the prevalence of M1 or M2 
macrophages is an indicator of whether adaptive or maladaptive repair is occurring (1, 
34, 68, 69).  Briefly, M1 macrophages are pro-inflammatory and promote renal injury, 
whereas M2 macrophages are anti-inflammatory and are essential for injury repair (1).  
Based on the roles of these subtypes, we would have expected M1 (iNOS expressing) 
macrophages to be prominent with repeated cisplatin dosing.  However, we found that 
Inos levels did not change with cisplatin treatment.  There was a peak in Arg-1 expression 
(M2 macrophages) after Dose 4, and Arg-1 levels were still elevated 6 months post 
cisplatin treatment.  Thus, macrophages present in the kidney after injury are M2 in 
nature.  This is poignant as the kidney has little to no Arg-1 expressed normally, and 
increases in Arg-1 can be specifically traced to M2 macrophages (89, 90).   
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Previous studies have indicated that M2 macrophages are reparative when there is 
short-term inflammation.  In our model chronic, progressive inflammation occurs, 
indicating M2 macrophages may be contributing to fibrosis with this type of injury.  This 
finding is not surprising as macrophages are known to secrete chemokines involved in the 
recruitment of fibroblasts, and can activate both resident and recruited myofibroblasts at 
the site of injury (70).  In an I/R study by Kim et al., there was a significant increase in 
F4/80+ macrophages during the recovery phase after I/R injury, but total number of 
macrophages continued to increase even after the recovery phase, suggesting their 
potential role in fibrotic injury (70).  There was a shift from M1 to M2 macrophages after 
the recovery phase, further highlighting the contribution of M2 subtype macrophages in 
fibrosis (70).  To validate the role of M2 macrophages and their contribution to fibrosis, 
Kim et al. depleted macrophages with liposome clodronate, which improved fibrosis 
(70).  Adoptive transfer studies with both M1 and M2 macrophages indicated that the 
fibrotic phenotype was only restored with M2 macrophages (70).  Our findings with our 
repeated cisplatin dosing model also indicate the importance of macrophages in 
fibrogenesis, and that specifically M2 macrophages are contributing to the progression of 
fibrosis.  
 While chronic inflammation and M2 macrophages can drive the development of 
renal fibrosis, this process is also largely mediated by TGFβ.  Tgfb1 levels significantly 
increased in the kidney after Dose 4 and remained elevated 6 months post cisplatin 
treatment.  TGFβ and CTGF are derived from senescent tubular cells that have undergone 
cell cycle arrest upon injury (1, 36, 37).  These pro-fibrotic growth factors can stimulate 
proliferation and differentiation of fibroblasts to myofibroblasts (1).  αSMA+ 
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myofibroblasts increased after Dose 4 and further increased 6 months post cisplatin 
treatment.  Myofibroblasts contribute to accumulation of collagen as evidenced by SR/FG 
staining, indicative of interstitial fibrosis.         
Interstitial fibrosis was detectable after Dose 4, and pathology scoring for 
interstitial fibrosis indicated increased severity 6 months post cisplatin treatment.  
Surprisingly, classical markers of interstitial fibrosis such as TGFβ, collagen levels, and 
fibronectin did not further increase.  However, periglomerular fibrosis developed 6 
months post cisplatin treatment therefore contributing to the overall presence of fibrosis, 
and highlighting the development of other glomerular pathologies with this model.  The 
development of interstitial fibrosis and glomerular pathologies after cisplatin treatment 
recapitulates outcomes in a porcine model of cisplatin treatment (91).  Mature, large 
white female pigs developed interstitial fibrosis in the deep cortex and medulla, and 
developed glomeruli with thickened Bowman’s capsules and capillary changes 24 weeks 
after intravaneous injection of low dose cisplatin (91, 92).  We saw a similar interstitial 
fibrosis pattern in the kidneys of mice with repeated cisplatin treatment after 6 month 
age-out, as well as glomerular changes at this time point.  Porcine kidneys are similar to 
human kidneys in structure, and have the ability to develop renal fibrosis and glomerular 
changes that are similar to what is seen with human CKD progression (93, 94).  However, 
renal studies with pigs are still relatively new, and mechanistic studies are difficult 
because genetically manipulated porcine models are still limited (93).  Since we are able 
to recapitulate a similar fibrotic phenotype with our mouse model, this further suggests 
that our repeated dosing regimen is a clinically relevant model of cisplatin 
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nephrotoxicity.  In addition, because this model utilizes mice, mechanistic studies are 
easier and more cost effective.     
The development of interstitial fibrosis is often preceded by endothelial 
dysfunction, a type of injury that occurs early in cisplatin-induced AKI.  Endothelial 
dysfunction also occurs in CKD and diabetes mellitus (77, 78).  Early dysfunction is 
marked by an increase in vasoconstrictors and adhesion molecules (78).  Endothelin-1 is 
a sensitive marker of endothelial perturbations, and increases in this vasoconstrictor leads 
to an increase in arterial stiffness, which if prolonged, could contribute to the 
development of atherosclerosis (77-79).  ICAM-1 and VCAM-1 promote inflammation 
by allowing leukocytes to adhere to endothelium (78).  This process is also promoted by 
MCP-1 (78).  With our model, slight changes in endothelin-1, VCAM-1, and ICAM-1 
can be seen after Dose 2 with our repeated cisplatin dosing regimen, these levels are 
further elevated after Dose 4, and remain slightly elevated 6 months post cisplatin, 
indicating persistent endothelial dysfunction (79).  Furthermore, CD31 expression is 
often lost in damaged endothelial cells.  CD31 IHC in the cortex revealed no overt 
changes to the endothelium, indicating endothelial dysfunction was occurring without 
causing actual damage to endothelial cells.  However, the role of CD31 in endothelial 
damage is complex.  Aside from endothelial cells, CD31 is highly expressed in 
leukocytes and tubule cells.  CD31 IHC in the medulla showed highly expressing CD31 
cells.  While further verification needs to be done to determine what these cells are, an 
increase in CD31 in this context is associated with the development of atherosclerotic 
lesions (79).  Atherosclerosis is another pathology associated with CKD, further 
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supporting the notion that repeated cisplatin administration leads to the development of 
progressive CKD. 
In conclusion, our data indicate the effects of repeated treatment with cisplatin, 
which better mimics the clinical dosing regimen, leads to adverse long-term effects 
without overt AKI.  Specifically, these effects include chronic inflammation, worsened 
interstitial fibrosis, endothelial dysfunction, declined kidney function, and glomerular 
pathologies associated with CKD.  This model is ideal for both identifying biomarkers for 
early injury detection, as well as potential targets to halt the development of CKD after 
cisplatin treatment.  This model also provides a clinically relevant model for testing 
current, potential kidney injury therapeutics that are being developed, with the ultimate 







AGING DOES NOT LEAD TO EXACERBATED AKI OR FIBROSIS 
INTRODUCTION 
In the United States, it is estimated that the elderly population will account for 
21% of the total population by 2030. In the context of AKI, advanced age is a major 
health concern.  The average age of an in-hospital patient with AKI is 75 years old, and 
the incidence of AKI increases with each decade of life (1).   Experimental data in mice 
have shown that aging is associated with chronic inflammation, increased oxidative 
stress, and mitochondrial dysfunction.  These physiological changes that occur with aging 
may contribute to increased susceptibility to AKI or cause exacerbated injury, ultimately 
resulting in a progressive loss of kidney function.  In particular, creatinine clearance 
begins to decrease after age 30 in humans, and many older people develop 
glomerulosclerosis, leading to a decline in GFR (95).   
The median age for all cancer diagnoses is 65, and most cancer diagnoses are 
made in patients over age 55.  Thus, this age group is more likely to be affected by 
cisplatin nephrotoxicity, and studying the effects of aging in cisplatin-induced kidney 
injury is important (52).  However, it is difficult to draw conclusions about the true risk 
of cisplatin-induced kidney injury in the elderly population because many patients have 
comorbidities that make them more susceptible to kidney injury even without cisplatin 
treatment, particularly cardiovascular disease and diabetes(24).  Thus, conclusions about 
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increased risk of cisplatin-induced AKI are limited.  Furthermore, experimental AKI 
aging studies often utilize mice at the end of their lifespan (18-24 months old) which do 
not represent the age group of patients that are often diagnosed with cancer and are most 
likely to receive cisplatin treatment for their malignancy.  In addition, these mouse 
studies often focus on I/R injury, which focuses mainly on the vascular injury that occurs 
in AKI rather than the multi-faceted injury that is seen with cisplatin treatment.  To 
improve on previous studies of cisplatin-induced AKI and aging, we utilized 40 week old 
FVB/n mice.  These mice better represent a middle-aged population who would be 
healthy enough to receive cisplatin.  We hypothesized that these mice, when treated with 
one, high dose of cisplatin (25 mg/kg), would have worsened AKI compared to 8 week 
old mice treated with the same dose.           
Aging is also associated with an increase in cellular senescence that pre-disposes 
the normal, aging kidney to the development of fibrosis (1, 95).  Previously, we have 
developed a more clinically relevant cisplatin dosing regimen that causes fibrosis and 
CKD (50).  Using this repeated dosing regimen, we wanted to determine whether 
repeated dosing of cisplatin in aged mice would result in worsened fibrosis.  To gain 
insight into this question, a cohort of 8 and 40 week old mice were treated with either 
saline or 7 mg/kg cisplatin once a week for four weeks and euthanized at Day 24.    
Data from these studies indicate that aged mice did not have worsened AKI 
compared to young mice.  However, 40 week old mice had basally elevated 
myofibroblasts and higher total collagen deposition compared to 8 week old mice. 
Administration of repeated, low dose cisplatin slightly elevated collagen deposition, but 
there was no difference in overall collagen deposition between cisplatin treated 8 week 
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and 40 week old mice.  Furthermore, aged mice treated with cisplatin had less of an 
inflammatory cytokine response compared to young mice.  The immune system plays an 
important role in kidney pathology, and chronic immune cell infiltration is heavily 
involved in the development of fibrosis (1, 38).  Immunohistochemistry staining for T 
cells and macrophages indicated there were more immune cells in the kidney with 
cisplatin treatment in 40 week old mice without overt fibrosis.  Taken together, our data 
indicate that aging is not associated with worsened AKI or fibrosis with cisplatin 
treatment. 
MATERIALS AND METHODS 
Animals.  Eight and 40 week old, male FVB/n mice were bred in house and provided 
graciously by Dr. Levi Beverly. Mice were maintained under standard laboratory 
conditions as previously described in Chapter 2. One cohort of both 8 and 40 week old 
mice were intraperitoneally injected at 8:00 a.m. with either one dose saline vehicle 
(0.9% saline in ddH2O) or cisplatin (25 mg/kg), and mice were sacrificed 72 hours after 
treatment (standard dosing regimen) [Fig 3.1].  Another cohort of mice was 
intraperitoneally injected at 8:00 a.m. with either saline vehicle (0.9% saline in ddH2O) or 
cisplatin (7 mg/kg) once a week for four weeks and euthanized at Day 24 (repeated 
dosing regimen) [Fig 3.2].  Mice were monitored for weight loss or high levels of 
discomfort/stress on a daily basis, and were euthanized if weight loss was greater than 









Antibodies.  The following antibodies were purchased from Cell Signaling (Beverly, 
MA) unless otherwise noted: cleaved caspase-3 (no. 9664), CCAAT/enhancer-binding 
protein homologous protein (CHOP; no. 2895), transforming growth factor (TGF)-β (no. 
Figure 3.1.  Standard dosing regimen of cisplatin.  8 and 40 week old male FVB 
mice were treated with either saline vehicle (0 mg/kg) or 25 mg/kg cisplatin once and 
euthanized 3 days (72 hours) after initial dosing.   
 
Figure 3.2.  Repeated dosing regimen of cisplatin.  8 and 40 week old male FVB 
mice were treated with either saline vehicle (0 mg/kg) or 7 mg/kg cisplatin once a 





3712S), fibronectin (F3648, Sigma-Aldrich, St. Louis, MO), and tubulin (SC-23948, 
Santa Cruz Biotechnology, Dallas, TX). 
Sample collection and storage. Urine was collected and stored at -80°C. Blood was 
collected, and plasma and kidney samples were prepared as previously described in 
Chapter 2.   
BUN determination.  Blood urea nitrogen (BUN) levels were determined in plasma 
using a kit from AMS Diagnostics (80146, AMS Diagnostics, Weston, FLA) per the 
manufacturer’s instructions. 
ELISAs.  ELISA for neutrophil gelatinase associated lipocalin (NGAL; DY1857, R&D 
Systems, Minneapolis, MN) was performed on urine samples using the manufacturers’ 
protocols. 
Gene expression.  Total RNA was isolated and cDNA was made as outlined in Chapter 
2.  Gene-specific cDNA was quantified using real-time QRTPCR and either pre-designed 
Taqman assays, or self-designed Sybr assays.  The following pre-designed primers were 
used: (Life Technologies, Grand Island, NY) Tnfα (Mm00443258_m1), Il6 
(Mm00446190_m1), Cxcl1 (Mm04207460_m1), Mcp-1 (Mm00441242_m1), Arg-1 
(Mm00475991_m1) and B2m (Mm00437762_m1).  Gene primers for Inos and kidney 
injury molecule-1 (Kim-1) were self-designed.  Primers were used in combination with 
either iTaq Universal Probes Supermix (172-5134, BioRad, Hercules, CA) or iTaq 
Universal Sybr Green Supermix (172-5124, BioRad, Hercules, CA).   
Protein Isolation/Quantification and Western Blot Analysis.  Protein was isolated and 
quantified as previously published (50).  Western blot analysis was performed as 
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previously published, using 1:5000 dilutions for primary antibodies and 1:40000 dilutions 
for secondary antibodies.  Proteins of interest were detected by chemiluminiscence 
substrate. 
Immunohistochemistry.  IHC stainings for αSMA and F4/80 were performed as 
previously described (Chapter 2 Materials and Methods).  For CD3, deparaffinization, 
antigen retrieval, and avidin/biotin blocking steps were performed as previously 
described for αSMA (Chapter 2 Materials and Methods).  After avidin/biotin blocking, 
slides were blocked with 5% normal goat serum in PBS (Invitrogen 31873) for one hour 
at room temperature.  Rat-anti-human CD3 (BioRad MCA1477) was diluted 1:100 in 
normal goat serum and applied to tissue sections.  Slides were incubated in primary 
antibody overnight at 4°C.  The next morning, slides were washed three times with PBS 
for 5 minutes each.  Goat-anti-rat biotinylated secondary antibody was diluted 1:250 in 
PBS and applied to slides for a one hour incubation.  During this time ABC reagent 
(Vectastain PK-4001) was prepared.  After incubation in secondary, slides were washed 
twice for five minutes in PBS.  ABC reagent was then applied to slides for thirty minutes, 
and slides were processed as previously described for αSMA IHC (Chapter 2 Materials 
and Methods).      
RESULTS 
Overall survival and weight loss in 8 and 40 week old mice treated with the standard 
dosing regimen of cisplatin.  AKI is associated with a high rate of mortality, ranging 
from 20-80%.  We hypothesized that 40 week old mice (aged mice) treated with high 
dose cisplatin would have decreased survival, and greater weight loss compared to 8 
week old mice (young mice) treated with cisplatin.  Young mice that received either 0 
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mg/kg or 25 mg/kg cisplatin survived to Day 3, at which point the young, cisplatin-
treated cohort had an average weight loss of 17.4% (Fig 3.3A,B).  While there was 100% 
survival in aged mice that received 0 mg/kg cisplatin, 80% of aged mice treated with high 
dose cisplatin survived (Fig 3.3A).  In addition, aged mice treated with cisplatin had lost 
an average of 11.9% of total body weight at Day 3, but weight loss was not significantly 
different than cisplatin-treated young mice (Fig 3.1B).  These data indicate that aged 
mice cannot tolerate high dose cisplatin as well as young mice due to mortality, and may 










Figure 3.3.  Survival and weight loss with the standard dosing regimen of cisplatin.  8 
and 40 week old male FVB mice were treated with either 0 mg/kg or 25 mg/kg cisplatin 
once.  (A) Percent survival until Day 3.  (B) Percent weight change in mice. Data are 
expressed as mean ± SEM; n=5-10.  Statistical significance was determined by Two-Way 




BUN and kidney injury levels increase in 8 and 40 week old mice treated with the 
standard dosing regimen of cisplatin.  During AKI, there is a rapid decline in kidney 
function that leads to the buildup of waste products in the blood which can be measured 
by either SCr or BUN.  Kidney function declines with normal aging, thus we 
hypothesized that aged mice would have increased baseline BUN levels compared to 
young mice.  We further hypothesized that, when treated with the standard dosing 
regimen of cisplatin, aged mice would have a more severe loss of kidney function 
compared to young mice treated with the same dosing regimen.  BUN levels significantly 
increased in both young and aged cisplatin-treated mice, but BUN levels were 
comparable between these two groups (Fig 3.4A). In addition, BUN was not basally 
elevated in aged mice compared to young mice (Fig 3.4A).   
 Without overt changes to BUN levels, kidney injury can be detected by more 
sensitive biomarkers like NGAL and KIM-1.  NGAL levels in urine increased 
approximately 15000-fold in young mice treated with cisplatin, but only 14.6-fold in aged 
mice compared to their respective control (Fig 3.4B).   Furthermore, NGAL levels were 
elevated in aged mice compared to young mice treated with 0 mg/kg cisplatin (Fig 3.4B).  
Kim-1 mRNA levels were elevated in young mice treated with cisplatin, and were further 
increased in aged mice treated with cisplatin.  Taken together, these data indicate that 
treatment of aged and young mice with the standard dosing regimen of cisplatin leads to a 
comparable loss of function, but higher levels of NGAL in young mice, and higher levels 
of Kim-1 in aged mice.  Since NGAL is also a marker of inflammation, aged mice may 










Figure 3.4.  Changes in kidney function and injury markers with the standard 
dosing regimen of cisplatin.  8 and 40 week old male FVB mice were treated with 
either 0 mg/kg or 25 mg/kg cisplatin once.  (A) BUN levels measured in plasma. (B) 
NGAL levels measured in urine. (C) Kim-1 mRNA levels measured in the kidney 
cortex via QRTPCR. Data are expressed as mean ± SEM; n=5-10.  Statistical 





Inflammatory cytokines and chemokines increase in 8 and 40 week old mice treated 
with the standard dosing regimen of cisplatin.  The activation of inflammatory 
cytokines and chemokines plays a major role in the pathogenesis of cisplatin-induced 
AKI.  Of note, TNFα increases early in kidney injury, and initiates the inflammatory 
response.  Tnfα mRNA levels increased approximately 10-fold in young mice treated 
with cisplatin, but only 4.7-fold in aged mice (Fig 3.5A).  Il6, another pro-inflammatory 
cytokine, increased 30.8-fold in young mice, but only 11.3-fold in aged mice (Fig 3.5B).  
Cxcl1 and Mcp-1, chemokines involved in the recruitment of immune cells to the site of 
injury, both increased in young and aged mice treated with cisplatin (Fig 3.5C,D).  
Interestingly, Mcp-1 levels were basally elevated in aged mice compared to young mice 
(Fig 3.5D).  Thus, these data indicate that aged mice have less of an inflammatory 



















Figure 3.5. Changes in inflammatory cytokine and chemokine levels with 
standard dosing regimen of cisplatin.  8 and 40 week old male FVB mice were 
treated with either 0 or 25 mg/kg cisplatin once.  Levels of (A) Tnfa, (B) Il6, (C) 
Cxcl1, and (D) Mcp-1 were measured in the kidney cortex via real-time QRTPCR. 
Data are expressed as mean ± SEM; n=5-10.  Statistical significance was determined 
by Two-Way ANOVA followed by Tukey post-test.  *P<0.05, **P< 0.01, 




Endoplasmic reticulum (ER) stress and apoptosis occur in the kidney in 8 and 40 
week old mice treated with the standard dosing regimen of cisplatin.  A hallmark of 
AKI is apoptotic cell death mainly affecting tubular epithelial cells. Furthermore, in I/R 
models of AKI, ER stress occurs thereby activating intrinsic cell death pathways.  CHOP 
is a transcription factor that is elevated during ER stress.  Aged mice had high, basal 
protein levels of CHOP compared to young mice (Fig 3.6).  When treated with cisplatin, 
CHOP levels increased in both young and aged mice (Fig 3.6). Cleaved caspase 3 is an 
established marker of apoptosis.  Treatment with cisplatin led to an increase in CC3 
levels in both aged and young mice (Fig 3.6). Taken together, these data indicate that 
while aged mice have high basal levels of ER stress, the levels of apoptosis that occur 
with cisplatin treatment in young and aged mice are comparable, indicating aged mice do 
























Figure 3.6.  Endoplasmic reticulum stress and apoptosis with standard dosing 
regimen of cisplatin.  8 and 40 week old male FVB mice were treated with either 0 
mg/kg or 25 mg/kg cisplatin once.  Protein levels of CHOP, CC3, and β-actin were 




Overall survival and weight loss in 8 and 40 week old mice treated with the repeated 
dosing regimen of cisplatin.  We have previously shown that 8 week old mice treated 
with repeated, low dose cisplatin (7 mg/kg once a week for four weeks) had a 100% 
survival rate at Day 24, and that these mice can be aged out at least six months after 
treatment with minimal weight loss.  Both young and aged mice treated with either 
repeated dosing of 0 or 7 mg/kg cisplatin had a 100% survival rate at Day 24 (Fig 3.7A).  
In addition, total weight loss for cisplatin treated mice in both age groups was less than 
10% (Fig 3.7B).  These data indicate that there is no difference in survival or weight loss 










Figure 3.7.  Survival and weight loss with the repeated dosing regimen of 
cisplatin.  8 and 40 week old male FVB mice were treated with either 0 mg/kg or 7 
mg/kg cisplatin once a week for four weeks.  (A) Percent survival until Day 24.  (B) 
Percent weight change in mice. Data are expressed as mean ± SEM; n=5-10.  





BUN and NGAL levels increase in 8 and 40 week old mice treated with the repeated 
dosing regimen of cisplatin.  We have previously shown that repeated, low dose 
cisplatin treatment causes a slight decline in kidney function, and an increase in NGAL 
levels indicative of kidney injury. BUN levels in young and aged mice increased with 
cisplatin treatment, although this increase was not significant (Fig 3.8A).  NGAL levels 
increased 51.2-fold in young mice, and only 9.3-fold in aged mice treated with cisplatin.  
Basally, NGAL levels were elevated 6.8-fold in aged mice compared to young mice (Fig 
3.8B).  KIM-1 is also a sensitive marker of kidney injury.  Kim-1 mRNA levels were 
increased 130-fold in young mice and 72-fold in aged mice compared to respective 
controls (Fig 3.8C).  Thus, data suggests that while injury markers are already elevated 
basally in aged mice, there is no difference in the level of kidney injury or loss of 



















Figure 3.8.  Changes in kidney function and injury markers with the repeated 
dosing regimen of cisplatin.  8 and 40 week old male FVB mice were treated with 
either 0 mg/kg or 7 mg/kg cisplatin once a week for four weeks.  (A) BUN levels 
measured in plasma. (B) NGAL levels measured in urine. (C) Kim-1 levels measured 
in kidney cortex via real-time QRTPCR.  Data are expressed as mean ± SEM; n=5-
10.  Statistical significance was determined by Two-Way ANOVA followed by 




Inflammatory cytokines and chemokines increase in 8 and 40 week old mice treated 
with the repeated dosing regimen of cisplatin.  Chronic inflammation is a major driver 
of fibrosis. We have shown that many of the same inflammatory cytokines and 
chemokines that play a role in cisplatin-induced AKI are also involved in the progression 
of kidney injury to CKD.  Tnfα mRNA levels increased 6-fold in young mice treated with 
cisplatin, but only 4-fold in aged mice (Fig 3.9A).  Il6 levels were elevated 8.8-fold in 
young mice treated with cisplatin, but only 1.8-fold in aged mice (Fig 3.9B).  
Inflammatory chemokines Cxcl1 and Mcp-1 significantly increased in both young and 
aged mice treated with cisplatin, and Mcp-1 was basally elevated in aged mice compared 
to young mice (Fig 3.9C,D).  Thus, there is less of an inflammatory cytokine response in 














Figure 3.9.  Changes in inflammatory cytokine and chemokine levels with the 
repeated dosing regimen of cisplatin.  8 and 40 week old male FVB mice were 
treated with either 0 mg/kg or 7 mg/kg cisplatin once a week for four weeks.  Levels 
of (A) Tnfa, (B) Il6, (C) Cxcl1, and (D) Mcp-1 were measured in the kidney cortex 
via real-time QRTPCR. Data are expressed as mean ± SEM; n=5-10.  Statistical 
significance was determined by Two-Way ANOVA followed by Tukey post-test.  




Fibrosis develops in 8 and 40 week old mice treated with the repeated dosing 
regimen of cisplatin.  Our group and others have demonstrated that repeated, low dose 
administration of cisplatin induces fibrosis.  Pathways of fibrogenesis are basally 
activated with normal kidney aging, and may contribute to the increased rate of CKD 
seen in aged populations.  Thus, we hypothesized that aged mice treated with the repeated 
dosing regimen of cisplatin would have an exacerbated fibrotic phenotype compared to 
young mice treated with cisplatin.  Activation of the TGFβ signaling pathway is one of 
the major contributors to the development of fibrosis. Furthermore, fibrosis is marked by 
an increase in ECM components, namely fibronectin and collagen.  Both TGFβ and 
fibronectin levels increased in young and aged mice treated with cisplatin (Fig 3.10A).  
Total collagen deposition as evidenced by SR/FG indicated that aged mice had higher 
collagen levels basally compared to young mice (3.8-fold increase) (Fig 3.10B).  
However, treatment with cisplatin led to a 5.3-fold increase in collagen in young mice, 
but only a 1.5-fold increase in aged mice, although overall collagen deposition levels 
were comparable between the two groups (approximately 11% Sirius red positive pixels) 
(Fig 3.10B).   
Myofibroblasts produce collagen during fibrogenesis.  Immunohistochemistry 
staining for αSMA indicated more myofibroblasts were present basally in aged mice 
compared to young mice (4.1-fold increase) (Fig 3.10C).  αSMA+ myofibroblasts 
increased 4.2-fold in young mice treated with cisplatin, but only 1.6-fold in aged mice 
(Fig 3.10C).  Overall, fibrosis was not worsened in aged mice treated with repeated 
dosing of cisplatin, even though αSMA+ myofibroblasts and collagen deposition were 






























Figure 3.10.  Fibrosis develops with the repeated dosing regimen of cisplatin.  8 
and 40 week old male FVB mice were treated with either 0 mg/kg or 7 mg/kg 
cisplatin once a week for four weeks. (A) Protein levels of TGFβ and fibronectin were 
determined in kidney cortex homogenate with Western blot.  (B) Total collagen levels 
were determine via SR/FG staining and quantified as % Sirius red positive pixels.  (C) 
Presence of myofibroblasts was determined by αSMA IHC, and quantified as % 
αSMA positive pixels. Data are expressed as mean ± SEM; n=5-10.  Statistical 




Increased CD3+ T cells and F4/80+ macrophages in the kidneys of aged mice treated 
with the repeated dosing regimen of cisplatin.  Immune cells after kidney injury play a 
dual role in exacerbating injury, as well as initiating adaptive repair responses.  We have 
previously shown that with repeated dosing of cisplatin, there is an increase in 
macrophages in the kidney that is associated with worsening fibrosis.  Aged mice treated 
with cisplatin had increased F4/80+ staining for macrophages compared to cisplatin-
treated young mice (Fig 3.11A).  ARG-1 and iNOS are markers for M2 and M1 
macrophages, respectively.  M1 macrophages are pro-inflammatory and lead to worsened 
injury, but M2 macrophages are involved in adaptive repair due to their anti-
inflammatory phenotype.  Inos mRNA levels did not increase in either cohort of mice 
treated with cisplatin; however, Arg-1 mRNA levels increased 5.3-fold in young mice, 
but only 1.8-fold in aged mice (Fig 3.11B,C).   
T cells (CD3+) are known to contribute to both cisplatin-induced AKI, and the 
development of CKD.  CD3+ T cells also increased in aged mice treated with cisplatin 
compared to young mice (Fig 3.11D).  Furthermore, these T cells formed clusters in aged 
mice, but not in young mice.  Taken together, IHC indicates there is more immune cell 
infiltration in old mice treated with cisplatin, even though fibrosis is not worsened in 








Figure 3.11.  Immune cells in the kidney with the repeated dosing regimen of 
cisplatin.  8 and 40 week old male FVB mice were treated with either 0 mg/kg or 7 
mg/kg cisplatin once a week for four weeks.  (A) Total macrophages were determined 
via F4/80 IHC.  Levels of (B) Inos and (C) Arg-1 were determined in the kidney 
cortex via real-time QRTPCR. (D) Total T cells were determined via CD3 IHC.  Data 
are expressed as mean ± SEM; n=5-10.  Statistical significance was determined by 





Renal aging is often marked by the development of glomerulosclerosis, tubular 
atrophy, increased cellular senescence, the development of interstitial fibrosis, and total 
nephron loss (1, 95).  These physiological changes ultimately culminate in decreased 
GFR, the inability to properly conserve and secrete sodium, and difficulties in proper 
concentration or dilution of urine (53, 95).  In the context of cisplatin-induced 
nephrotoxicity, Wen et al found that lung cancer patients receiving one dose of cisplatin 
had a 9.2% decrease in GFR, and that age was the only risk factor examined to have a 
significant relationship with decline in kidney function after the first round of cisplatin 
treatment (96). However, these patients had also received other chemotherapeutics known 
to cause kidney injury.  Of note, 83 patients that received cisplatin also received 
gemcitabine, a well-known inducer of nephrotoxicity (96, 97).  Studies such as this 
highlight the need to better understand the true contribution of cisplatin to worsened 
kidney injury with aging.    
Furthermore, most experimental studies that examine the effects of aging in 
regards to increased injury are performed in very old animals, making it difficult to 
translate these findings into the clinical setting where the median age of all cancer 
diagnoses is 65 years old (52).  Wen et al demonstrated that 18 month old C57BL/6J 
mice developed more severe kidney injury when treated with 15 mg/kg cisplatin 
compared to 3 month old mice (96).  These aged mice had increased BUN levels when 
treated with cisplatin, an increase in TLR4 mediated signaling, increased cisplatin 
accumulation in the kidney, and a 35% decrease in protein levels of MATE1, an efflux 
transporter that is responsible for removal of cisplatin from the kidney (96).     
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Despite concern for increased susceptibility to kidney injury in the aged 
population, several clinical studies have indicated that aging may not be as great of a 
concern.  First, the rate of nephrotoxicity/AKI in pediatric cancer patients treated with 
cisplatin is comparable to the rate seen in adults.  Skinner et al found that 50% of 
children treated with either cisplatin or carboplatin had nephrotoxicity post-treatment, ad 
36.4% of these patients had a decreased GFR indicative of CKD (32).  The rate of 
cisplatin nephrotoxicity in adult cancer patients ranges from 20-30%, and approximately 
20% of all adult patients diagnosed with AKI will progress to CKD (9, 10).    
In a study by Thyss et al, patients aged 80-87 without underlying cardiovascular 
disease did not have an increased rate of cisplatin nephrotoxicity compared to younger 
populations (aged 55 or less) receiving a similar dosing regimen (98).  This study further 
highlighted that comorbidities such as cardiovascular disease may contribute to kidney 
function changes that are often associated with normal aging, and may attribute to 
increased susceptibility to cisplatin nephrotoxicity.   
In addition, Hrushesky et al reported that patients 60-70 years of age treated with 
cisplatin had an average 21 ml/min decline in creatinine clearance, but this decline was 
30 ml/min in patients aged 50 or younger, indicating a greater loss of kidney function in 
the younger cohort of patients (99).  Hrushesky et al concluded that these 60-70 year olds 
may be slightly protected from cisplatin nephrotoxicity because the external medulla is 
highly preserved despite aging, and that this was the main site of cisplatin concentration 
in older patients (99).  Finally, with aging there was no change in overall clearance of 
cisplatin, suggesting concern for treating patients of advanced age may not be as serious 
as previously believed. 
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In this study, we utilized 40 week old FVB mice as our aged cohort.  This 
represents a middle age cohort of mice, as the average lifespan of FVB mice is 16-20 
months.  We believe using this age of mouse better reflects the cohort of patients who are 
diagnosed with cancer that are eligible to receive cisplatin treatment.  Our data in aged 
mice treated with cisplatin indicate that there is a difference in both the inflammatory 
response and immune cell recruitment after injury, without worsening of kidney injury or 
an overt change in loss of kidney function.    
Of note, we saw no age-dependent changes in basal BUN levels, nor difference in 
BUN between 8 and 40 week old mice treated with either dosing regimen of cisplatin.  
This challenges the belief that normal kidney aging leads to a decline in kidney function, 
and highlights that changes in kidney function in older patients may be due to underlying 
comorbidities.  Furthermore, although nephron mass is lost with normal aging, 
compensatory hypertrophy of the remaining nephrons may help maintain normal kidney 
function, especially when kidney injury occurs (99). 
When measuring kidney injury with sensitive biomarkers, we found that aged 
mice treated with the standard dosing regimen of cisplatin had much lower levels of 
NGAL overall, and these levels were comparable to those in 8 and 40 week old mice 
treated with the repeated dosing regimen of cisplatin.  However, basal levels of NGAL 
were higher in aged mice compared to young mice.  Recent studies have indicated that 
NGAL may be a better biomarker for inflammation, especially as TNFα can directly 
upregulate NGAL expression (100).  Thus, NGAL may be indicative of an altered 
inflammatory response with cisplatin in aged mice.  Indeed, Tnfa mRNA levels in 40 
week old mice treated with the standard dosing regimen of cisplatin were significantly 
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less than those of 8 week old mice treated with the same regimen.  This coincides with 
data presented in an I/R study by Jang et al, in which TNFa levels were lower with 
ischemic injury in both 6 and 12 month old C57BL/6J mice compared to 3 month old 
mice with the same injury (101).  This trend was also apparent with the repeated dosing 
regimen of cisplatin.  Furthermore, Il6 mRNA levels were lower in 40 week old mice 
compared to 8 week old mice treated with either dosing regimen of cisplatin.  However, 
in a study of normal aging and changes to the immune micromilieu, IL6 levels were 
basally increased in both 6 and 12 month old mice, although these elevated levels did not 
result in worsened ischemic injury in aged mice (101).   Taken together, our data indicate 
that aged mice have a decreased inflammatory response to cisplatin treatment. 
Chronic inflammation also contributes to renal fibrosis (1).  Forty week old mice 
had increased collagen deposition and more myofibroblasts present compared to 8 week 
old mice basally.  However, treatment with repeated dosing of cisplatin did not lead to 
overt collagen deposition, or the presence of more myofibroblasts in aged mice.  This 
outcome may correlate with the lack of a robust inflammatory response with cisplatin 
treatment.  Interestingly, there was more immune cell infiltration of CD3+ T cell and 
F4/80+ macrophages in the kidneys of 40 week old mice treated with the repeated dosing 
regimen of cisplatin than in 8 week old mice. Classically, a robust inflammatory response 
corresponds to increased immune cell infiltration which can further drive the 
inflammatory response.  However, both T cells and macrophages play diverse roles in 
kidney injury, and it has been reported that T lymphocytes have decreased function with 
aging, adapting an “immuosenescent” phenotype (1, 9).  Of note, we saw an increase in 
M2 macrophages as measured by Arg-1 mRNA expression.  Arg-1 levels were higher in 
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young mice treated with repeated doses of cisplatin, even though total macrophages were 
higher in the aged group treated with cisplatin.  This finding may further support an 
immunosuppressive phenotype, as we hypothesize that macrophages in aged mice have 
less activity and thus lower production of ARG-1, although this must be confirmed in 
future studies. 
Taken together, the cisplatin dosing regimens discussed here represent both AKI 
and CKD, two disease states that are thought to be more likely to occur in aged 
populations.  Overall, this study indicates that aging does not greatly alter kidney injury 
or changes in function with both the standard and repeated dosing regimens of cisplatin.  
Thus, treating older patients with cisplatin may not result in a more severe kidney injury 
phenotype or increased rate of nephrotoxicity.  Furthermore, worsened injury and higher 
susceptibility to injury may be the result of comorbidities aside from age, such as 
underlying cardiovascular disease, diabetes, polypharmacy, or genetic polymorphisms-






TREATMENT WITH REPEATED DOSING OF CISPLATIN CAUSES WORSENED 
FIBROSIS IN A MOUSE MODEL OF KRAS4BG12D LUNG ADENOCARCINOMA 
THAT CANNOT BE PREVENTED WITH ERLOTINIB 
INTRODUCTION 
 The overall survival of cancer patients has improved over the last ten years, but 
with this increase in survival comes a potentially greater risk for patients to have long-
lasting side effects from the cancer itself, or the treatment of cancer.  Of note, cancer 
patients have a higher rate of AKI than critically ill patients without cancer (102).  
Furthermore, cancer patients often have more severe forms of AKI that will often require 
renal replacement therapy, and the 28-day mortality rate in these patients ranges from 66-
88% (102, 103).  In a Danish study of 1.2 million cancer patients, rates of AKI were 
found to be highest in patients with renal cell carcinoma, leukemia, and liver cancer 
(103).  Of the patients that had one of these types of cancer, the overall one year risk of 
AKI was 17.5%, and this increased to 27% over a five year period (103).  In addition, 5% 
of patients with cancer required dialysis within the first year of diagnosis. 
 The increased susceptibility to AKI in cancer patients may be attributed to the 
greater probability of being exposed to known causes of AKI.  For example, sepsis-
induced AKI is more prevalent in cancer patients (102).  Those who develop sepsis are 




contrast-induced nephrotoxicity is also high in cancer patients because they often 
undergo imaging procedures during the initial cancer screening and course of treatment.   
 Cancer patients also have a higher pre-test probability for certain causes of AKI.  
For one, tumor lysis syndrome (TLS)-induced AKI is specific to cancer patients (102). 
Tumor lysis syndrome occurs most often during the treatment of cancer, as dying cancer 
cells release their intracellular components into the bloodstream (104).  This leads to the 
development of hyperkalemia, hypocalcemia, hyperphosphatemia, and hyperuricemia.  
Furthermore, the formation of crystals of uric acid and calcium phosphate can cause 
intratubular obstructions when filtered through the kidney (104).  This in turn can lead to 
a decline in kidney function and cause an inflammatory response.  The combination of 
crystal obstruction and a robust inflammatory response is associated with renal 
vasoconstriction and reduced renal blood flow, ultimately culminating in severe kidney 
injury and functional loss. 
 The use of nephrotoxic chemotherapeutics and other oncotherapies is also specific 
to cancer patients.  Of note, cisplatin is one of the most widely used chemotherapeutics 
for the treatment of solid tumor cancers.  Approximately one third of cancer patients will 
develop AKI after the first dose of cisplatin, and 20-30% will develop nephrotoxicity 
throughout the course of treatment with cisplatin, regardless of the type of cancer (9, 10).  
Since only cancer patients receive cisplatin treatment, it is important to study cisplatin-
induced AKI experimentally in a mouse model of cancer.  However, work in this field is 
very limited.   
In a seminal study by Pabla et al, 7 and 8 week old athymic female mice were 




treated with 10 mg/kg cisplatin weekly (105).  Only 30% of mice with ovarian cancer 
survived to week 4 with cisplatin treatment, and none were able to receive a fifth dose of 
cisplatin.  These mice also had severe loss of renal function as measured by SCr and 
BUN, and a high level of apoptosis in the kidney (105).  Utilizing a subcutaneous model 
of lung adenocarcinoma, Ravichandran et al reported that mice treated with 10 mg/kg 
cisplatin once a week for four weeks developed severe kidney injury as measured by 
NGAL levels in the serum, decreased kidney function, and high levels of acute tubular 
necrosis and apoptosis (55).   
Both studies described here utilize xenograft or subcutaneous models of cancer, 
which have several limitations for studying the systemic effects of cancer.  To address 
these limitations for incorporating cancer into a clinically relevant mouse model of 
cisplatin-induced kidney injury, a better approach would be to use a transgenic mouse 
model with a driver cancer mutation relevant to human cancers.  The use of a transgenic 
model would provide a way to examine cancer in its original location in a mouse with an 
intact immune system.  In addition, the development of cancer in most transgenic mouse 
models is gradual and better mimics the progression of the human disease. Thus, 
transgenic mouse models of cancer provide a clinically relevant way to study cancer as a 
systemic disease, and the potential impact this may have on kidney outcomes with 
cisplatin-induced kidney injury. 
To incorporate the differential effects cancer may have on cisplatin-induced 
kidney injury, we utilized a Tet-O-Kras4bG12D transgenic mouse model of lung 
adenocarcinoma.  Lung cancer is often treated with low dose cisplatin, making it a 




higher risk of TLS-associated AKI, the risk of cisplatin-induced AKI in patient with lung 
cancer is not well established (106, 107).  Based on studies that indicate cancer patients 
have an increased risk of AKI, we hypothesized that mice with lung adenocarcinoma 
treated with our repeated dosing regimen of cisplatin would have a higher level of kidney 
injury and subsequent loss of function compared to non cancer mice.  As we have 
established that repeated administration of cisplatin causes fibrosis, and many of the same 
processes involved in AKI are also involved in the development of fibrosis, we further 
hypothesized that mice with lung adenocarcinoma treated with cisplatin may have 
worsened fibrosis as well, compared to mice treated with cisplatin without lung 
adenocarcinoma. 
To test these hypotheses, 40 week old male and female mice with and without 
lung adenocarcinoma (non cancer and cancer) were treated with either 0 or 7 mg/kg 
cisplatin once a week for four weeks, and euthanized on Day 24.  Mice with cancer had a 
lower rate of survival to Day 24, high levels of NGAL in the urine after Dose 1 and 2, 
and worsened fibrosis compared to non cancer mice treated with the same cisplatin 
dosing regimen.  To address why mice with cancer treated with cisplatin may have 
worsened fibrosis, we examined the EGFR signaling pathway.  Repeated or sustained 
activation of EGFR is known to induce renal fibrosis in several experimental mouse 
models (74, 108, 109).  Western blot analysis indicated that cancer mice treated with 
cisplatin had increased EGFR levels in the kidney, and subsequently high activation of 
EGFR.  Downstream EGFR signaling pathways were also differentially activated in 
cancer mice treated with cisplatin.  Thus, we hypothesized that inhibition of EGFR 




in cancer mice.  Using erlotinib, an FDA-approved EGFR inhibitor, we found that 
inhibition of EGFR caused severe AKI in both cancer and non cancer mice treated with 
cisplatin.  Thus, these data indicate that mice with cancer have worsened kidney injury 
when treated with our clinically relevant dosing regimen of cisplatin that cannot be 
prevented by pharmacological inhibition of EGFR.             
MATERIALS AND METHODS 
Preparation of methylcellulose and erlotinib.  For methylcellulose, 100 μl Tween 80 
was dissolved in 100 ml ddH2O with constant stirring.  Once dissolved, 500 mg 
methylcellulose (M0512-100G, Sigma) was added to the solution, and was allowed to stir 
at room temperature overnight.  Methylcellulose solution was then filter sterilized and 
kept at 4°C for 3 months.  Erlotinib HCl (S1023, Selleck Chemicals) was dissolved in 
methylcellulose at a 5 mg/ml concentration.  Erlotinib solution was sonicated in a 37°C 
sonication bath for 10 minutes, and was then stored at 4°C away from light for up to a 
week. 
Animals.  For cancer studies, an inducible transgenic mouse model of mutant Kras 
(Kras4bG12D) lung adenocarcinoma on the FVB/n mouse background was used (Fig 
4.1).  Briefly, 40 week old male and female single transgenic mice (tet-o-Kras4bG12D or 
CCSP-rtTA) or double transgenic mice (tet-o-Kras4bG12D-CCSP-rtTA) were 
intraperitoneally injected at 8:00 a.m. with either saline vehicle (0.9% saline in ddH2O) or 
cisplatin (7 mg/kg) once a week for four weeks and euthanized at Day 24.  Mice were 
monitored for weight loss or high levels of discomfort/stress on a daily basis, and were 




For erlotinib studies, 40 week old male and female single or double transgenic 
mice were intraperitoneally injected at 8:00 a.m. with either saline vehicle (0.9% saline in 
ddH2O) or cisplatin (7 mg/kg) once on Day 1.  These mice also received methylcellulose 
vehicle or 25 mg/kg erlotinib intraperitoneally on Day 1-6, and were euthanized on Day 7 
(Figure 4.2).  Mice were monitored for weight loss or high levels of discomfort/stress on 







Figure 4.1.  Inducible, transgenic model of mutant Kras lung adenocarcinoma.  
In this double transgenic model, the reverse tetracycline transactivator (rtTA) is 
constitutively expressed in type II lung epithelial cells via a Clara cell specific 
promoter (CCSP).  rtTA, in the presence of doxycycline, binds to the tet operon of 
Kras4bG12D (KrasG12D), thereby activating expression of mutant Kras.  Only mice 
that have both transgenes for CCSP-rtTA/tet-o-Kras4bG12D and that are on a 








Sample collection and storage. Urine was collected and stored at -80°C. Blood was 
collected, and plasma and kidney samples were prepared as previously described in 
Chapter 2.   
BUN determination.  Blood urea nitrogen (BUN) levels were determined using a kit 
from AMS Diagnostics (80146, AMS Diagnostics, Weston, FLA) per the manufacturer’s 
instructions. 
Figure 4.2.  Cisplatin and erlotinib dosing regimen.  Non cancer and cancer mice were 
treated with one dose of either 0 or 7 mg/kg cisplatin on Day 1.  These mice were then 
treated with either 0 or 25 mg/kg cisplatin on Days 1-6.  On Day 7, mice were euthanized 




ELISAs.  ELISA for neutrophil gelatinase associated lipocalin (NGAL; DY1857, R&D 
Systems, Minneapolis, MN) was performed on urine samples using the manufacturers’ 
protocol. 
Gene expression.  Total RNA was isolated and cDNA was made as outlined in Chapter 
2.  Gene-specific cDNA was quantified using real-time RTPCR and either pre-designed 
Taqman assays, or self-designed Sybr assays.  The following pre-designed primers were 
used: (Life Technologies, Grand Island, NY) were used:  Tnfα (Mm00443258_m1), 
Cxcl1 (Mm04207460_m1), Mcp-1 (Mm00441242_m1), and B2m (Mm00437762_m1).  
Primers were used in combination with iTaq Universal Probes Supermix (172-5134, 
BioRad, Hercules, CA). 
Antibodies.  The following antibodies were purchased from Cell Signaling (Beverly, 
MA) unless otherwise noted: epidermal growth factor receptor (EGFR, no. 9664), 
pEGFR Y1068 (no. 2895), c-jun N-terminal kinase (JNK, no.9252), pJNK (no.4668), 
nuclear factor kappa-light-chain enhancer of activated B cells (NFκB, no.8242), pNFκB 
(no.3033), transforming growth factor (TGF)-β (no. 3712S), fibronectin (F3648, Sigma-
Aldrich, St. Louis, MO), and tubulin (SC-23948, Santa Cruz Biotechnology, Dallas, TX). 
Protein Isolation/Quantification and Western Blot Analysis.  Protein was isolated and 
quantified as previously published (50).  Western blot analysis was performed as 
previously published, using 1:5000 dilutions for primary antibodies and 1:40000 dilutions 





Preparation of kidney sections for histology/IHC.  Kidney sections were fixed, 
embedded, and cut as previously described in Chapter 2.   
Immunohistochemistry.  αSMA was performed as previously described in Chapter 2.   
Sirius red/ fast green staining for total collagen.  SR/FG staining was performed as 
previously described in Chapter 2. 
Statistical analysis.  Data are expressed as means ±SEM for all experiments.  Multiple 
comparisons of normally distributed data sets were analyzed by two way ANOVA, as 
appropriate, and group means were compared using Tukey posttests.  The criteria for 
statistical differences were: *P< 0.05, **P< 0.01, ***P< 0.001, and ****P< 0.0001.  For 
erlotinib studies, data sets were analyzed using one way ANOVA.   
RESULTS 
Overall survival is decreased in cancer mice treated with repeated dosing of 
cisplatin.  We have previously published that mice treated with 7 mg/kg cisplatin once a 
week for four weeks have a 100% survival rate to Day 24.  Forty week old non cancer 
mice treated with either 0 or 7 mg/kg cisplatin had 100% survival at Day 24 (Fig 4.3).  
Cancer mice treated with 0 mg/kg cisplatin had 83% survival, and cancer mice treated 
with 7 mg/kg cisplatin had 47% overall survival (Fig 4.3).  These data indicate that 
cancer mice treated with cisplatin have a substantial decrease in survival rate compared to 


















Figure 4.3.  Treatment with repeated administration of cisplatin decreases overall 
survival in cancer mice.  Forty week old male and female mice with and without 
cancer were treated with either 0 or 7 mg/kg cisplatin once a week for four weeks.  
Mice that showed obvious signs of discomfort/stress, or that had ≥20% weight loss 





BUN and NGAL levels increase with repeated administration of cisplatin in non 
cancer and cancer mice.  BUN is a standard marker of kidney function, and NGAL is an 
FDA-approved biomarker for kidney injury.  AKI is more prevalent in cancer patients 
when compared to critically ill patients without cancer.  Furthermore, cancer mice treated 
with cisplatin had worsened survival compared to non cancer mice treated with cisplatin 
(Fig 4.3). Therefore, we hypothesized that BUN and NGAL levels would be higher in 
cancer mice treated with cisplatin than in non cancer mice treated with cisplatin.  BUN 
levels increased in both non cancer and cancer mice treated with 7 mg/kg cisplatin, but 
there was no difference in BUN levels between these two groups (Fig 4.4A).  At Day 24, 
NGAL levels increased 21-fold in non cancer mice treated with cisplatin, but only 4-fold 
in cancer mice treated with cisplatin that survived to Day 24 (Fig 4.4B).  However, 
NGAL levels were increased 16-fold and 76-fold at Day 6 and 13 respectively in cancer 
mice treated with cisplatin compared to non cancer mice treated with cisplatin (Fig 4.4C).  
Thus, cancer mice treated with cisplatin have earlier, worsened kidney injury compared 










Figure 4.4.  Kidney function and injury in non cancer and cancer mice treated 
with repeated dosing of cisplatin.   Forty week old male and female mice with and 
without cancer were treated with either 0 or 7 mg/kg cisplatin once a week for four 
weeks.  (A) BUN levels measured in blood plasma.  (B) NGAL levels measured in 
urine at Day 24. (C) NGAL levels measured in urine at Day 6 and 13 in non cancer and 
cancer mice treated with 7 mg/kg cisplatin. Statistical significance was determined by 





Increase in inflammatory cytokine and chemokine levels in non cancer and cancer 
mice treated with repeated dosing of cisplatin.  Inflammation is a major 
pathophysiology involved in cisplatin-induced AKI and CKD.  We hypothesized that 
since cancer mice treated with cisplatin had worsened kidney injury, that these mice 
would also have higher levels of inflammatory cytokines and chemokines.  Tnfα, ll6, 
Mcp-1, and Cxcl1 were increased with cisplatin treatment in both non cancer and cancer 
mice (Fig 4.5A-D).  Thus, cancer mice do not have a worsened inflammatory response 




















Figure 4.5.  Changes in inflammatory cytokine and chemokine levels in non cancer 
and cancer mice treated with repeated dosing of cisplatin.   Forty week old male 
and female mice with and without cancer were treated with either 0 or 7 mg/kg cisplatin 
once a week for four weeks.  Levels of (A) Tnfα, (B) Il6, (C) Mcp-1, and (D) Cxcl1 
measured in the kidney cortex via QRTPCR. Statistical significance was determined by 
Two-Way ANOVA followed by Tukey post-test.  * p< 0.05, **p<0.01, ***p<0.001, 





Cancer mice develop worsened renal fibrosis when treated with the repeated dosing 
regimen of cisplatin.  We have previously shown that repeated administration of low 
dose cisplatin induces fibrosis.  TGFβ is a canonical signaling pathway in fibrogenesis, 
and TGFβ protein levels increased with cisplatin treatment in non cancer mice, and were 
further elevated in cancer mice treated with cisplatin (Fig 4.6A).  Fibronectin, an ECM 
component, increased in the same manner (Fig 4.6A).  To further confirm the presence of 
fibrosis, SR/FG staining for total collagen deposition and αSMA IHC for myofibroblasts 
was performed.  Treatment with cisplatin led to an increase in collagen deposition in non 
cancer mice, but levels of collagen were significantly higher in cancer mice treated with 
cisplatin (Fig 4.6B).  Similarly, cancer mice treated with cisplatin also had increased 
αSMA positivity (Fig 4.6C). Taken together, these data indicate that cancer mice treated 
with cisplatin develop worsened renal fibrosis when compared to non cancer mice treated 
















Figure 4.6.  Development of fibrosis in non cancer and cancer mice treated with 
repeated dosing of cisplatin.   Forty week old male and female mice with and 
without cancer were treated with either 0 or 7 mg/kg cisplatin once a week for four 
weeks. (A) Protein levels of TGFβ and fibronectin in kidney cortex homogenates were 
determined by Western blot.  (B) SR/FG stain for total collagen levels and 
quantification of percent Sirius red positive pixels.  (C) αSMA IHC for total 
myofibroblasts and quantification of percent αSMA positive pixels. Statistical 






Epidermal growth factor receptor (EGFR) levels increase in cancer mice treated 
with repeated dosing of cisplatin.  EGFR is upregulated and activated to increase 
cellular proliferation of injured proximal tubule cells.  However, sustained activation of 
EGFR plays a role in fibrogenesis.  Western blot data indicated increased EGFR protein 
levels in the kidneys of cancer mice treated with cisplatin (Fig 4.7A).  In addition, cancer 
mice treated with cisplatin also had increased pEGFR Y1068 levels, indicating activation 
of EGFR, compared to non cancer mice treated with cisplatin (Fig 4.7A).  To further 
confirm the differential role of EGFR in cancer mice treated with cisplatin, we utilized 
markers of EGFR downstream signaling pathways.  Activation of JNK (pJNK) and NFκB 
p65 (pNFκB p 65) was higher in cancer mice treated with cisplatin than non cancer mice 
(Fig 4.7B).  Therefore, these data indicate the role of EGFR in worsened renal fibrosis in 













Figure 4.7.  EGFR activation and downstream signaling pathway activation in non 
cancer and cancer mice treated with repeated dosing of cisplatin.  Forty week old 
male and female mice with and without cancer were treated with either 0 or 7 mg/kg 
cisplatin once a week for four weeks. (A) Protein levels of EGFR, pEGFR (Y1068), 
and tubulin and (B) pJNK, JNK, pNFκB p65, NFκB p65, and tubulin were determined 





Inhibition of EGFR leads to worsened survival and severe weight loss when mice are 
treated with cisplatin. Cancer mice treated with cisplatin had increased EGFR and 
subsequently increased EGFR activation (Fig 4.7A).  We hypothesized that inhibition of 
EGFR with erlotinib in these mice would protect from the development of fibrosis, or 
decrease the severity of fibrosis that occurrs with cisplatin.  To test this hypothesis, 
cohorts of non cancer and cancer mice were treated with either 0 mg/kg cisplatin and 0 
mg/ kg erlotinib (V), 0 mg/kg cisplatin and 25 mg/kg erlotinib (E), 7 mg/kg cisplatin and 
0 mg/kg erlotinib (C), or 7 mg/kg cisplatin and 25 mg/kg erlotinib.  One dose of cisplatin 
and one dose of erlotinib was administered at Day 0, followed by either 0 or 25 mg/kg 
erlotinib Day 1-6.  Both non cancer and cancer mice treated with V, E, or C had 100% 
survival to Day 7 (Fig 4.8A).  However, non cancer mice treated with C+E had 67% total 
survival at Day 6, and cancer mice treated with C+E had 80% survival at Day 6 (Fig 
4.8A).  By Day 7, all mice had to be euthanized in the C+E treatment groups.  Weight 
loss in C+E treated non cancer mice was 17%, and 11% in cancer mice (Fig 4.8B).  These 
data indicate that mice cannot survive combinatorial treatment with cisplatin and 













Figure 4.8.  Overall survival and weight loss with cisplatin + erlotinib.  Forty 
week old male and female mice with and without cancer were treated with either 
saline vehicle once (V), 25 mg/kg erlotinib once a day for 6 days (E), 7 mg/kg 
cisplatin once (C), or 7 mg/kg cisplatin once and 25 mg/kg erlotinib for 6 days (C+E). 
(A) Percent survival of mice to Day 7.  (B) Total percent weight loss at Day 7. 
Statistical significance was determined by One-Way ANOVA followed by Tukey 





BUN and NGAL levels are markedly increased in non cancer and cancer mice 
treated with combinatorial cisplatin and erlotinib treatment.  Based on poor survival 
outcomes and weight loss, we hypothesized that both cohorts of mice treated with C+E 
would have increased BUN and NGAL levels, indicative of severe AKI.  BUN was 
slightly increased with cisplatin treatment in non cancer and cancer mice, but was highly 
elevated in both cohorts treated with C+E (Fig 4.9A).  Similarly, NGAL levels were 
markedly increased with C+E treatment in both groups (Fig 4.9B).  Thus, mice treated 
















Figure 4.9.  Kidney injury and loss of function with cisplatin + erlotinib.  Forty 
week old male and female mice with and without cancer were treated with either saline 
vehicle once (V), 25 mg/kg erlotinib once a day for 6 days (E), 7 mg/kg cisplatin once 
(C), or 7 mg/kg cisplatin once and 25 mg/kg erlotinib for 6 days (C+E). (A) BUN levels 
measured in plasma.  (B) NGAL levels measured in urine. Statistical significance was 





Inflammatory cytokine and chemokine levels in non cancer and cancer mice treated 
with cisplatin+erlotinib.  Treatment with repeated administration of cisplatin causes an 
inflammatory response marked by increases in Tnfα, Il6, Mcp-1, and Cxcl-1.  In non-
cancer mice, Tnfα was significantly increased with cisplatin treatment, but levels were 
not elevated with C+E treatment (Fig 4.10A).  Mcp-1 and Cxcl-1 were elevated with 
cisplatin (Fig 4.10B,C).  Mcp-1 was slightly elevated with C+E, but Cxcl-1 levels were 
increased approximately 100-fold in non cancer mice (Fig 4.10B,C).  In mice with 
cancer, there was not an increase in Tnfα levels in any treatment group (Fig 4.10A).  
However, there was a slight increase in Mcp-1 levels with cisplatin treatment, and Cxcl-1 
was slightly elevated with C+E treatment (Fig 4.10B,C).  Additionally, non cancer and 
cancer mice treated with erlotinib had decreased Mcp-1 levels.  These data indicate a 
differential activation of inflammatory cytokines and chemokines in non cancer and 




















Figure 4.10.  Changes in inflammatory cytokine and chemokine levels with 
cisplatin+erlotinib. .   Forty week old male and female mice with and without cancer 
were treated with either saline vehicle once (V), 25 mg/kg erlotinib once a day for 6 
days (E), 7 mg/kg cisplatin once (C), or 7 mg/kg cisplatin once and 25 mg/kg erlotinib 
for 6 days (C+E).  Levels of (A) Tnfα, (B) Mcp-1, and (C) Cxcl-1 were measured in 
the kidney via QRTPCR.  Statistical significance was determined by One-Way 
ANOVA followed by Tukey post-test; *** indicates p<0.001. 






 Cancer patients have a higher rate of AKI compared to critically ill patients 
without cancer (102, 103).  Of the causes of AKI, drug-induced nephrotoxicity is more 
prevalent, as only patients with cancer receive chemotherapy.  Cisplatin has a high rate of 
nephrotoxicity in cancer patients, leading to the development of AKI in 20-30% of 
patients.   
Studies utilizing experimental models of cancer to study the development of 
cisplatin nephrotoxicity are limited.  Furthermore, these experiments are usually 
performed in xenograft or subcutaneous cancer models which do not allow for studies of 
cancer as a systemic disease.  Mouse xenograft models are not ideal for studying the 
systemic effect cancer may have in relation to the development of AKI.  First, tumor cells 
injected subcutaneously will develop at the site of injection, rather than the original site 
from which the cancer cells were derived.  The tumor microenvironment plays a crucial 
role in the response of the cancer to chemotherapy, thus this relationship cannot be 
studied (110, 111).  Furthermore, xenograft models that utilize human cancer cell lines 
require the use of immunocompromised mice for proper engraftment.  A major 
component of cisplatin-induced kidney injury and subsequent recovery is the immune 
cell response (9, 10, 15).  Not being able to incorporate this essential component may 
affect kidney injury outcomes.  
 To improve on these limited xenograft studies, we utilized a transgenic mouse 
model of Kras4bG12D lung adenocarcinoma combined with our clinically relevant 
dosing regimen of cisplatin.  Mice with transgenes for both Tet-o-Kras4bG12D and 




the diet.  This is a relevant cancer model because patients with lung cancer are often 
treated with repeated, lower doses of cisplatin.  Furthermore, previous studies have 
indicated that there is lung/kidney crosstalk that may suggest a worsened kidney injury 
phenotype in the context of lung cancer (112).  Specifically, AKI is associated with 
respiratory failure, prolonged ventilation, and prolonged ventilator weaning.  Lung 
complications are associated with an increased mortality risk in the setting of AKI (112-
114).  This is attributed to the fact that the lung contains a vast microcapillary network, 
making it susceptible to inflammatory cytokines and chemokines released from injured, 
distant organs.  Furthermore, injury to the kidney may stimulate leukocytes that can 
exacerbate lung injury and vice versa (113, 114).  However, the true risk of cisplatin-
induced kidney injury in lung cancer patients is largely unknown.  The study we present 
here enables us to study cancer as a systemic disease, and potential effects it may have on 
distal organs as the result of cisplatin-induced kidney injury.   
 Our data indicate that mice with cancer have a higher death rate when treated with 
cisplatin than do age-matched non cancer mice.  This seems counterintuitive as cisplatin 
treatment is supposed to treat cancer.  However, analysis of kidney injury revealed a high 
peak in NGAL levels at Day 6 and 13 in cancer mice treated with cisplatin, indicative of 
an AKI phenotype.  Mice that were able to survive to Day 24 had relatively low levels of 
NGAL, suggesting some mice fare better with cisplatin than others.  Although we are 
uncertain as to why some mice with cancer die early with cisplatin treatment, we 
hypothesize this may due to the development of TLS or acute lung injury.  Examining 




This study is the first to examine the development of fibrosis indicative of CKD in 
the context of cancer. Cancer mice treated with cisplatin had worsened fibrosis compared 
to non cancer mice treated with cisplatin.  Taken together, this study indicates that cancer 
is a risk factor for the development of both cisplatin-induced AKI and subsequent CKD.  
This aligns with patient data in which AKI is more prevalent in patients with cancer 
(103). 
 Delving into the mechanism as to why cancer mice treated with cisplatin have 
worsened kidney injury outcomes, we found expression of EGFR in cancer mice treated 
with cisplatin was more pronounced than in non cancer mice.  This differential 
expression of EGFR in cancer mice makes it a desirable target for treatment of cisplatin-
induced kidney injury.  Overexpression and over-activation of EGFR have both been 
documented in many experimental forms of AKI and CKD, including cisplatin 
nephrotoxicity, I/R, and folic acid nephropathy models (74, 108, 109, 115, 116).  
However, the effects of blocking EGFR and its activation remain controversial, due to the 
fact that EGFR plays different roles in AKI and fibrosis.  
 Using a proximal tubule-specific EGFR knockout (KO) mouse in combination 
with the experimental I/R model, Chen et al found that although initial injury levels were 
comparable after surgery in both WT and KO mice, KO mice had more injury present 6 
days post-surgery compared to WT mice (115).  Thus, this study indicates that EGFR 
plays an important role in recovery after injury.  However, sustained activation of EGFR 
can promote renal fibrosis (74, 108).  In the angiotensin II model of renal fibrosis, EGFR 
is constitutively activated (108).  Constitutive activation of EGFR promoted ERK 




fibrosis.  Pharmacological inhibition of EGFR decreased collagen levels and activation of 
TGFβ signaling (108).  Thus, inhibition or KO of EGFR in the context of AKI may 
exacerbate injury, but be protective in the development of fibrosis.  
 Many studies that have examined the potential renoprotective effects of EGFR 
inhibition have used pharmacological inhibition with small molecule inhibitors.  Of these, 
erlotinib is commonly used.  Erlotinib is a small molecule receptor tyrosine kinase 
inhibitor (RTKI) with high specificity to EGFR (117).  Erlotinib competes with 
adenosine triphosphate to inhibit EGFR autophosphorylation, thereby blocking activation 
of EGFR-mediated downstream signaling pathways (117).  Ultimately, this culminates in 
G0/G1 cell cycle arrest, an increase in p27 expression, and apoptosis.   
 Due to its apoptotic effects, erlotinib is commonly used in the treatment of cancer, 
specifically in cancers that have EGFR mutations, including colon, pancreas, breast, 
ovarian, NSCLC, and bladder cancers (117-119).  Clinical trials have shown elrotinib is 
also effective in cancers without EGFR mutations.  Furthermore, erlotinib has commonly 
been tested in combination with platinum-containing chemotherapeutic regimens.  In 
A549 lung cancer cells, erlotinib had additive effects when combined with gemcitabine, 
and erlotinib was synergistic with cisplatin (120).  In a Phase III clinical trial, patients 
with NSCLC received either cisplatin+gemcitabine+placebo or 
cisplatin+gemcitabine+erlotinib as a first line treatment.  Patients that received 
cisplatin+gemcitabine+erlotinib did not show a significant increase in overall survival 
(120).  However, in a Phase III study where erlotinib was used as a maintenance 




overexpressing cancers showed a 40.8% 12 week disease control rate, compared to the 
placebo group (27.4% 12 week disease control rate) (118).   
 The potential anti-tumor efficacy of erlotinib with other chemotherapeutics, 
especially cisplatin, makes it an even more attractive target for its use as a renoprotective 
agent.  In a study by Wada et al, rats were treated with one dose of erlotinib and cisplatin 
to determine if erlotinib was renoprotective.  By Day 4, rats treated with erlotinib and 
cisplatin had better renal function and decreased tubulointerstitial injury compared to rats 
that received cisplatin alone (121).  In addition, erlotinib and cisplatin combinatorial 
treatment caused less apoptosis and a decrease in proliferating cells, indicative of less 
renal injury.  Erlotinib and cisplatin treatment also decreased mRNA expression levels of 
profibrogenic markers, specifically TGFβ (121).  However, erlotinib in combination with 
cisplatin had no overall effect on inflammatory cytokine expression, or immune cell 
infiltration. 
 While the study by Wada et al highlights the promise of erlotinib as a 
renoprotective agent, our study indicates that administration of erlotinib with cisplatin 
exacerbates nephrotoxicity and causes severe AKI compared to mice treated with 
cisplatin alone.  Combinatorial treatment of cisplatin+erlotinib caused severe kidney 
injury and loss of function.  Our data coincides with clinical data that has shown that 
patients treated with cisplatin+gemcitabine+erlotinib have an increase in renal failure 
compared to patients who receive chemotherapy without erlotinib, although increased 
renal failure was attributed to insufficient hydration caused by erlotinib-associated 
diarrhea (120).  Other studies have indicated that small molecule receptor tyrosine kinase 




renal injury (122).  In an FDA toxicity study, there were 63 reported cases of renal 
impairment with erlotinib, and the most common renal side effects included 
hypertension, hyponatremia, and hypokalemia (123).  Furthermore, Dimke et al found 
that treating mice with high dose erlotinib for 23 days caused a decrease in Mg2+ serum 
levels associated with altered magnesium handling (124).  In a clinical trial examining the 
toxic profile of erlotinib and sorafenib (a VEGFR-2 inhibitor), 34% of patients developed 
hypophosphatemia compared to treatment with sorafenib alone (119).   
Although it is unclear how erlotinib causes these electrolyte imbalances, we 
hypothesize that cisplatin+erlotinib may cause severe AKI via damage to proximal tubule 
cells in combination with electrolyte imbalance.  While we did not measure electrolyte 
levels in the serum in this study, this is a necessary and important follow-up study.  
Furthermore, while our study indicates that erlotinib is not a good choice as a 
renoprotective agent in cisplatin-induced kidney injury, it may have some utility as an 
injury ameliorating drug in our model.  Western blots indicated an increase in EGFR and 
pEGFR (Y1068) at Day 24 in cancer mice treated with cisplatin, suggesting there may be 
sustained activation of EGFR.  Since sustained activation of EGFR promotes renal 
fibrosis, treating mice with erlotinib once fibrotic processes are already activated may 
hinder further injury or ameliorate fibrosis that has already developed.   
Taken together, our data highlight the importance of studying cisplatin-induced 
kidney injury by utilizing a cancer mouse model.  Cancer mice have worsened kidney 
outcomes compared to non cancer mice treated with our repeated dosing regimen of 
cisplatin.  Our data recapitulates clinical data that indicates there is a greater rate of AKI 




due to the fact that cancer patients are more likely to be exposed to kidney insults, our 
data suggests that, at least in the context of lung cancer, there may be an interaction 







Cisplatin has been a mainstay in the treatment of many solid tumor cancers either 
alone or in combination with surgery, radiation, or other chemotherapeutics since the 
1970’s (2).  While cisplatin is a potent therapeutic for treating cancer, its dose-limiting 
side effect of nephrotoxicity causes AKI in 20-30% of patients.  AKI itself is a risk factor 
for the development of CKD, a progressive disease marked by the development of renal 
fibrosis (26, 57).  Both AKI and CKD often require dialysis and are associated with an 
increased mortality risk, however, there are no pharmacological interventions for either 
form of kidney injury (9, 27, 57).  For cisplatin-induced kidney injury specifically, we 
believe that this deficit in therapeutic approaches is because of the lack of a relevant 
experimental mouse model of cisplatin nephrotoxicity.  Thus, the overall goal of this 
dissertation was to develop a clinically relevant mouse model of cisplatin-induced kidney 
injury in hopes of identifying novel therapeutic targets for the prevention or treatment of 
the disease.   
To develop this clinically relevant model, we had two main objectives: (1) 
develop a dosing regimen of cisplatin that recapitulates how patients receive cisplatin, 
and (2) include aging and cancer, as these are pertinent risk factors for AKI.  Our work 
and the work of others have shown that low dose, repeated administration of cisplatin 




wanted to determine if it was possible to develop bona fide CKD after cisplatin-induced 
AKI.  Thus, we treated mice with our repeated dosing regimen of cisplatin (7 mg/kg 
cisplatin once a week for four weeks) and allowed mice to age for 6 months post-
treatment.  At this time point, mice had progressive interstitial fibrosis and inflammation, 
persistent endothelial and tubular injury, and the development of glomerular pathologies 
that contributed to a significant decline in renal function (Table 5.1).  Thus, this work 
validates the notion that AKI can progress to CKD, and that only mild, sub-clinical injury 
is necessary for the development of fibrosis. Our work indicates that more patients treated 













Furthermore, it has been hypothesized that the risk of developing certain forms of 
AKI increases with aging.  The median age of all cancer diagnoses is 65, and therefore 
this population may be at risk for developing exacerbated cisplatin-induced kidney injury, 
although previous patient and experimental data have been unclear about what the true 
risk is.  Combining our clinically relevant dosing regimen and aging, we have provided a 
comprehensive study of aging and cisplatin nephrotoxicity.  Our data indicate that aged 
mice do not develop worsened AKI or fibrosis indicative of CKD compared to young 
mice (Table 5.2A,B).  However, aged mice have higher levels of collagen deposition, 
Table 5.1.  Overview of injury with the repeated dosing regimen of cisplatin.  
After Dose 2 of cisplatin, there is minimal damage to the kidney.  However, after 
Dose 4 there is severe endothelial dysfunction and tubular damage, and fibrosis 
develops.  Six months after treatment, inflammation and fibrosis are worsened, and 




myofibroblasts, and injury basally in the kidney (Table 5.2B).  Furthermore, while 
repeated administration of cisplatin in aged mice leads to increased immune cell 
infiltration, there was less of an inflammatory cytokine response, and fibrosis was not 
exacerbated (Table 5.2).  This lack of difference between young and aged mice in terms 
of injury may suggest that age is not as big of a patient risk factor for cisplatin 













Table 5.2.  Differences between 8 and 40 week old mice treated with either the 
standard dosing or repeated dosing regimen of cisplatin.  (A) With the standard 
dosing regimen of cisplatin, aged mice have a decreased overall survival, and less of 
an inflammatory response.  (B) With repeated dosing, collagen levels and 
myofibroblasts are basally elevated in 40 week old mice, but these mice do not 
develop worsened fibrosis compared to 8 week old mice treated with cisplatin.  In 




In addition to the incorporating aging into our model, it was important to also 
include cancer.  Cancer patients have a greater rate of developing AKI in general than 
critically ill patients without cancer, and only patients with cancer receive cisplatin.  
Using a transgenic mouse model of lung adenocarcinoma in combination with our 
repeated dosing regimen of cisplatin, we found that cancer mice had decreased survival, 
increased kidney injury, and worsened renal fibrosis compared to non cancer mice treated 
with the same dosing regimen (Table 5.3A).  Further analyses revealed an upregulation of 
EGFR and pEGFR Y1068 in cancer mice treated with cisplatin, making EGFR a good 
potential therapeutic target.  However, administration of erlotinib, an FDA-approved 
EGFR inhibitor, in combination with cisplatin caused severe AKI (Table 5.3B).  Thus, 












In total, work outlined in this dissertation highlights the need for designing 
clinically relevant animal models of disease.  Using our newly established mouse model 
of cisplatin-induced kidney injury, we hope to identify novel therapeutic targets for 
treating AKI/CKD, as well as identifying potential biomarkers for monitoring disease 
progression.  Furthermore, utilization of this model to test already developed therapeutics 
Table 5.3.  Differences in injury of non cancer and cancer mice treated with the 
repeated dosing regimen of cisplatin.  (A)  Mice with cancer have decreased overall 
survival to Day 24 and higher levels of NGAL earlier with cisplatin treatment 
compared to non cancer mice.  Cancer mice treated with cisplatin that survive to Day 
24 also have worsened fibrosis. (B)  Combinatorial treatment with cisplatin + erlotinib 




for the treatment of AKI/CKD will hopefully lead to better results once these drugs are 
put into clinical trials. 
STRENGTHS/LIMITATIONS 
STRENGTHS 
The work presented here is, to our knowledge, the first comprehensive 
experimental study of cisplatin-induced kidney injury leading to CKD.  Previous work in 
this field has focused on AKI using a non-physiologically relevant mouse model of 
cisplatin nephrotoxicity.  Data published with this standard model of cisplatin 
nephrotoxicity have indicated that targeting apoptosis or necrosis is important for 
protecting against AKI.  However, pharmacological inhibitors of apoptosis have not fared 
well in clinical trials.  We have demonstrated that when a more clinically relevant dosing 
regimen of cisplatin is used, there is minimal cell death.  Thus, our data challenges the 
field of cisplatin-induced AKI research to seek out alternative therapies for the prevention 
of nephrotoxicity- namely targeting fibrotic pathways instead of cell death pathways.   
Our work also challenges the notion that aging is a risk factor for worsened 
kidney injury with cisplatin treatment.  Data in this field is rather limited, and most of the 
work focuses on the development of AKI.  However, our data indicate that in both the 
standard model of cisplatin-induced AKI and our newly developed model in which mice 
develop fibrosis indicative of CKD, that middle-aged mice do not have worsened kidney 
outcomes when treated with cisplatin.  This is particularly interesting because aged mice 
do have kidney injury, higher collagen levels, and more myofibroblasts present basally in 




are somewhat protected from the development of kidney injury, although we do not know 
the mechanism by which this is occurring. 
Finally, we are the first to demonstrate that mice with cancer treated with our 
clinically relevant dosing regimen of cisplatin develop more severe kidney injury and 
fibrosis compared to non cancer mice treated with cisplatin.  Our novel approach was to 
use a transgenic mouse model of lung adenocarcinoma, which is preferable to xenograft 
models.  Utilizing a transgenic model of cancer enables us to study cancer as a systemic 
disease and truly understand the effect cancer itself may have on distal organs, 
particularly the kidney.  Furthermore, our data with this cancer model suggest that cancer 
is a risk factor for kidney injury.  This recapitulates human data studies where patients 
with cancer have a higher rate of AKI than non cancer, critically ill patients.  
Incorporation of cancer with repeated, low dose administration of cisplatin is the crux of 
making the model presented in this dissertation translationally relevant.  We have further 
demonstrated this point by identifying EGFR as a therapeutic target for protecting against 
the development of fibrosis.  However, inhibition of EGFR with erlotinib caused severe 
AKI.  Again, this recapitulates data from clinical trials that have shown erlotinib in 
combination with other chemotherapeutics or targeted therapies can cause electrolyte 
imbalances which can contribute to functional loss of the kidney. 
LIMITATIONS 
 While we believe that our model has the potential to be a paradigm shift in the way 
we study and think about cisplatin-induced kidney injury, there are several limitations 
associated with the model.  First, we do not know how the dose given to mice compares to 




is difficult to calculate dose equivalencies between mice and humans.  This is further 
hindered by a difference in cisplatin clearance.  Mice have 2.4-20 times greater plasma 
concentration of cisplatin than humans, but the half-life of cisplatin is also shorter in mice 
(125).  Thus, there is a faster distribution of cisplatin to tissues in mice, suggesting mice 
may be more susceptible to nephrotoxicity than humans.  Regardless, our repeated dosing 
regimen combined with dosing regimen of others, regardless of dose, all indicate that 
fibrosis is the result of repeated administration of cisplatin. 
While our model indicates that fibrosis, not cell death, is the result of repeated 
administration of cisplatin, very little clinical data exists to indicate that patients also 
develop fibrosis with cisplatin alone.  The lack of data is due to the fact that many patients 
have comorbidities that may predispose them to CKD and the development of fibrosis, 
namely cardiovascular disease or diabetes regardless of cisplatin treatment.  In addition, 
kidney biopsies are not routinely taken during the course of cisplatin treatment.  In fact, we 
tried to utilize kidney biopsy banks from O’Brien centers across the U.S. and were unable 
to find any samples from patients who did not also have diabetes or other comorbidities. 
 Finally, our model utilizes FVB/n background mice, but most renal studies are 
performed in C57BL/6J mice.  C57BL/6J mice are known to be resistant to some forms of 
renal fibrosis.  In a model of Type 1 diabetic nephropathy utilizing streptozocin, C57BL/6J 
mice did not develop interstitial fibrosis (126).  In a model of BSA-induced renal fibrosis, 
C57BL/6J mice had significantly lower levels of collagen type 1 expression, a major 
component of extracellular matrix produced during fibrosis (59, 127, 128).  In fact, treating 
C57BL/6J mice with 7 mg/kg cisplatin once a week for four weeks (repeated dosing 




increasing the dose to 9 mg/kg is sufficient to induce a similar level of fibrosis to what 
FVB/n mice develop with 7 mg/kg (Fig 5.1).  Thus, the utility of our model is flexible by 







     While we have worked extensively to characterize and validate our clinically relevant 
mouse model of cisplatin-induced kidney injury, the mechanisms underlying some of our 
results have yet to be elucidated.  The future directions are outlined below:   
Figure 5.1.  Development of renal fibrosis in FVB/n and C57BL/6J mice.  
C57BL/6J mice are known to be resistant to the development of renal fibrosis in many 
experimental models of kidney injury.  FVB/n mice develop interstitial fibrosis with 
repeated dosing of 7 mg/kg cisplatin, but C57BL/6J do not develop fibrosis with this 




1. Understanding the role of immune cells in the development of renal fibrosis.  
Immune cells play an essential role in kidney injury, and we have shown that 
increased infiltration of macrophages into the kidney is associated with the 
development of fibrosis.  However, in the context of aging, immune cell 
infiltration does not necessarily indicate that injury or fibrosis will be worse.  In 
fact, despite more immune cell infiltration of macrophages and T cells in the 
kidneys of aged mice treated with repeated dosing of cisplatin, the increase in 
collagen levels is rather low.  In this way, it might be interpreted that aged mice 
may be protected from the development of fibrosis due to an immunosuppressive 
phenotype as evidenced by less of an inflammatory response with cisplatin 
treatment.  In order to gain further insight into this hypothesis, it would be 
interesting to replace bone marrow in aged mice with bone marrow from young 
mice and vice versa, thereby giving these mice a different immune system.  We 
would expect that if immunosuppression protects from the development of 
fibrosis that young mice with aged mouse bone marrow would have less fibrosis. 
Additionally, aged mice with young bone marrow would develop more fibrosis.  
This would challenge the commonly held dogma that an intact, fully functioning 
immune system is important for injury repair and better prognoses. 
2. Determine the efficacy of erlotinib as an injury-ameliorating strategy.  Data 
outlined in Chapter 4 indicate that inhibiting EGFR activation after one, low dose 
of cisplatin (7 mg/kg) exacerbates kidney injury, leading to a severe AKI 
phenotype.  This is not surprising as EGFR and its downstream signaling 




Thus, blocking the activation of EGFR means that injury cannot be resolved.  In 
contrast, sustained activation of EGFR promotes the development of fibrosis.  At 
Day 24, EGFR is still activated in cancer mice treated with cisplatin.  Thus, using 
erlotinib to block fibrotic processes would provide a novel strategy for 
intervention during cisplatin-induced kidney injury.  In order to test this, we are 
currently treating cancer mice with our repeated dosing regimen of cisplatin.  
Starting after the fourth dose of cisplatin, mice were administered 25 mg/kg 
erlotinib once a day for a month (Fig 5.2).  We hypothesize that mice that 
received erlotinib post-cisplatin treatment will have less fibrosis.  Thus, erlotinib 





3. Explore the role of circadian dysregulation in cisplatin-induced kidney 
injury, especially in the context of cancer.  Using the same transgenic mouse 
model of lung adenocarcinoma discussed in Chapter 4, Masri et al found that lung 
adenocarcinoma operated as an endogenous reorganizer of circadian functions, 
specifically liver metabolism (129).  The function of the kidney is also tightly 
controlled by normal circadian rhythms.  In addition, cisplatin has been a subject 
Figure 5.2.  Erlotinib after repeated dosing of cisplatin.  Mice with cancer were 
administered cisplatin (7mg/kg) once a week for four weeks.  At Day 24, 25 mg/kg 




of several chronopharmacological studies.  Lѐvi et al reported that administration 
of cisplatin in the late afternoon after doxorubicin versus the morning after 
doxorubicin resulted in less nephrotoxicity with no effect on therapeutic efficacy 
(130).  Furthermore, Li et al found that patients with NSCLC that received 
cisplatin in the late evening had less neutropenia, gastrointestinal toxicity, and 
leucopenia that coincided with higher rate of cisplatin clearance at this time point 
(131).  Combining these studies, we hope to understand if circadian rhythms in 
the kidney are altered with cancer, and how this may have an effect on kidney 
injury, particularly the development of fibrosis, during the course of cisplatin 
treatment.  Preliminary data indicate that repeated administration of cisplatin 
causes a switch in expression levels in the core clock protein- BMAL1 (Fig 5.3A).  
Furthermore, BMAL1 levels are altered basally in cancer mice (Fig 5.3B).  
Understanding how these changes may alter injury outcomes will provide 
valuable insight into using the time of day as a way to find a balance between 


























Figure 5.3.  Alterations in BMAL1, an essential regulator of circadian rhythms.  
(A) Levels of Bmal1 measured via QRTPCR in kidneys treated with saline or 
cisplatin at various times of day.  (B) Bmal1 levels measured in non cancer and 
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clinical Kidney Injury Induced by Repeated Cisplatin Administration Results in 
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 Sharp CN, Siskind LJ.  Developing Better Mouse Models to Study Cisplatin-
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 Sharp CN, Doll MA, Dupre TV, Beverly LJ, and Siskind LJ.  Worsened renal 
fibrosis in Kras4bG12D lung adenocarcinoma-bearing mice treated with 
repeated dosing of cisplatin may be EGFR-mediated. 
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